Florida International University

FIU Digital Commons
FIU Electronic Theses and Dissertations

University Graduate School

7-7-2010

Blood-Brain Barrier in vitro Model: A Tissue
Engineering Approach and Validation
Zhiqi Zhang
Florida International University, zzhan001@fiu.edu

DOI: 10.25148/etd.FI10081003
Follow this and additional works at: https://digitalcommons.fiu.edu/etd
Recommended Citation
Zhang, Zhiqi, "Blood-Brain Barrier in vitro Model: A Tissue Engineering Approach and Validation" (2010). FIU Electronic Theses and
Dissertations. 246.
https://digitalcommons.fiu.edu/etd/246

This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in
FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact dcc@fiu.edu.

FLORIDA INTERNATIONAL UNIVERSITY
Miami, Florida

BLOOD-BRAIN BARRIER IN VITRO MODEL: A TISSUE ENGINEERING
APPROACH AND VALIDATION

A dissertation submitted in partial fulfillment of the
requirements for the degree of
DOCTOR OF PHILOSOPHY
in
BIOMEDICAL ENGINEERING
by
Zhiqi Zhang
2010

To: Dean Amir Mirmiran
College of Engineering and Computing
This dissertation, written by Zhiqi Zhang, and entitled Blood-Brain Barrier in vitro
Model: A Tissue Engineering Approach and Validation, having been approved in respect
to style and intellectual content, is referred to you for judgment.
We have read this dissertation and recommend that it be approved.

_______________________________
Ophelia Weeks
_______________________________
Nikolaos Tsoukias
_______________________________
Wei-Chiang Lin
_______________________________
Yen-Chih Huang
_______________________________
Chenzhong Li, Major Professor

Date of Defense: July 7, 2010
This dissertation of Zhiqi Zhang is approved.
_______________________________
Dean Amir Mirmiran
College of Engineering and Computing
_______________________________
Interim Dean Kevin O’Shea
University Graduate School

Florida International University, 2010

ii

DEDICATION
I dedicate this dissertation to my parents and all the animals that have to be
sacrificed for scientific researches.

iii

ACKNOWLEDGMENTS
I wish to thank the members of my committee for their patience and support.
Special thanks to Dr. Chenzhong Li – if it weren’t because of him, I won’t be able to
accomplish my dissertation. And I’m always grateful for Dr. Eric Crumpler – if it weren’t
because of him, this dissertation won’t even exist.

iv

ABSTRACT OF THE DISSERTATION
BLOOD-BRAIN BARRIER IN VITRO MODEL: A TISSUE ENGINEERING
APPROACH AND VALIDATION
by
Zhiqi Zhang
Florida International University, 2010
Miami, Florida
Professor Chenzhong Li, Major Professor
This dissertation evaluated the feasibility of using commercially available immortalized
cell lines in building a tissue engineered in vitro blood-brain barrier (BBB) co-culture
model for preliminary drug development studies. Mouse endothelial cell line and rat
astrocyte cell lines purchased from American Type Culture Collections (ATCC) were the
building blocks of the co-culture model. An astrocyte derived acellular extracellular
matrix (aECM) was introduced in the co-culture model to provide a novel in vitro
biomimetic basement membrane for the endothelial cells to form endothelial tight
junctions. Trans-endothelial electrical resistance (TEER) and solute mass transport
studies were engaged to quantitatively evaluate the tight junction formation on the invitro BBB models. Immuno-fluorescence microscopy and Western Blot analysis were
used to qualitatively verify the in vitro expression of occludin, one of the earliest
discovered tight junction proteins. Experimental data from a total of 12 experiments
conclusively showed that the novel BBB in vitro co-culture model with the astrocyte
derived aECM (CO+aECM) was promising in terms of establishing tight junction
formation represented by TEER values, transport profiles and tight junction protein

v

expression when compared with traditional co-culture (CO) model setups and endothelial
cells cultured alone. Experimental data were also found to be comparable with several
existing in vitro BBB models built from various methods. In vitro colorimetric
sulforhodamine B (SRB) assay revealed that the co-cultured samples with aECM resulted
in less cell loss on the basal sides of the insert membranes than that from traditional coculture samples. The novel tissue engineering approach using immortalized cell lines
with the addition of aECM was proven to be a relevant alternative to the traditional BBB
in vitro modeling.
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CHAPTER I INTRODUCTION
1.1 General Statement of Research Problem Area
According to World Health Organization (WHO), brain diseases such as cerebrovascular disease and Alzheimer’s disease, as well as epilepsy and brain tumors have
become a significant healthcare problem in western countries. According to the Brain
Tumor Society, over 200,000 people are diagnosed with a primary or metastatic brain
tumor in the US each year. The drug development for the central nervous system (CNS)
will have to grow over five times to be comparable to those of the cardiovascular
diseases(1). The biggest challenge in brain drug delivery research is to overcome the
brain’s effective protective mechanism collectively known as the blood-brain barrier
(BBB) (2-5). With the existence of the (BBB), which greatly restricts the influx of almost
everything into the brain, the treatment methods are largely limited on the drug delivery
aspect. Current available drug delivery methods are usually risky, highly invasive, can
lead to irreversible side effects or allow very limited distribution of drug within the brain
tissue -- for example, injecting hyper osmotic sugar solutions (Mannitol) into a brain
artery, inserting catheters to pump drugs into the brain and implanting drug eluting
wafers after surgical tumor removal(6). The limited treatment methods have also
disappointed the hope of cure of patients. It is necessary and important to create a
feasible and repeatable research model for the blood-brain barrier along the journey of
conquering brain diseases.
Despite numerous models established by different research labs on different cell
types, it is still difficult to conclude a specific model to be the optimal prototype. The in
vitro models do not always show promising consistency and are reported to poorly
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correlate with the in vivo studies(7). In this particular study, in vitro BBB co-culture
model will be established utilizing commercially available cell lines. Astrocytes derived
acellular extracellular matrix (aECM) will be introduced as a biomimetic basement
membrane of the endothelial cells for better seeding and induction of brain
microvasculature endothelial cells features. Essential characteristics of the in vitro coculture model will be evaluated to validate the feasibility of the study. Study will be
focused on morphological study of endothelial monolayer, trans-endothelial electrical
resistance (TEER) value to evaluate the tightness of intercellular junctions, expression of
characteristic tight junction protein such as Occludin using Western Blot and immuno
fluorescent microscopy as well as transport studies for various compounds across the in
vitro model membrane, and etc.
1.2 Significance of the Study
According to the complexity in patients and the problem of cost efficiency, it is
always better to perform in vitro studies before going into in vivo studies. With the brain
disease being major killer and the blood-brain barrier remaining the major obstacle for
medicine treatment, a valid in vitro model will help greatly in understanding the disease
as well as drug development. The use of BBB in vitro culture assays in early safety
assessment of drugs is a growing field (5). There are many existing so-called BBB in
vitro models but none of them are perfect. The aim of my study is to provide a cost
effective yet relatively easy to obtained source of BBB in vitro model for preliminary
drug studies. Commercially available immortalized cell lines will be employed as the
building blocks of the in vitro co-culture model, this approach will save significant
amount of work in the initial preparation of cells in comparison with primary cells
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obtained directly from live animals. At the same time, in the current society where animal
rights is more and more an important issue, the method utilizing passages of
immortalized cell lines is consistent with people’s value which could lead to prolonged
development of the current research. In addition, the introduction of aECM in
engineering the in vitro co-culture model is a novelty in the BBB in vitro modeling. This
approach enables better mimic of the brain environment with the aECM serving as the
basement membrane for the endothelial cells. The importance of extracellular matrix
(ECM) has been now more and more widely accepted. This particular approach is a
practical utilization of the ECM in the real experiment and has shown promising results.
This practice will aid better understanding and wider utilization of ECM in the scientific
studies.
1.3. Research Premise and Methodology
The aim of this study is to provide researchers with a reliable and reproducible in
vitro blood-brain barrier model for preliminary drug delivery studies. Two types of cell
lines will the employed in engineering an in vitro co-culture model. The co-culture model
will be built on a cell culture insert cultured in cell culture well plates. One type of cell
will be seeded on the top of insert membrane while the other type of cell seeded on the
other side of the insert membrane. The two types of cell lines are immortalized
endothelial cells and astrocytes purchased from American Type Culture Collection
(ATCC). Astrocytes derived aECM is engineered in the lab and employed in the coculture for improved in vitro BBB characteristics. Multiple combinations of cell culture
setups, such as endothelial cells cultured alone (EC), astrocytes cultured alone (AS), coculture without aECM (CO) and co-culture with aECM (CO+aECM) will be tested for
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the decision of an optimal model. While the CO+aECM sample is the proposed ultimate
goal, other setups as well as blank inserts are used as side-by-side controls.
All the sample setups are subjected to several different tests to evaluate the
formation of tight junction as the most important characteristic of the BBB. First of all,
TEER measurements are performed daily starting the second day after the endothelial
cells on the top of insert membranes are seeded. This test serves as a screening method in
the initial evaluations for all the different sample setups. Setups with consistent low
TEER values will be excluded from further studies as BBB is featured on high TEER
values. After the initial TEER value screening, the remaining sample setups will be
evaluated by transport study testing several different compounds such as calcein, caffeine
and Doxorubicin (DOX). The transport profiles are recorded as one of but not solely the
main reference to evaluate the BBB formation. Qualitative assays such Western Blot and
immuno-fluorescent microscopy will also be employed in the assessment to identify the
existence of Occludin, one of the earliest discovered tight junction proteins. Western blot
compares the expression level of Occludin in the cell lysates collected at the end of
culture period from different setups, while immuno-fluorescent microscopy enables one
to see the existence of Occludin directly on the sample membranes. At last, a brief SRB
assay will be utilized to quantify the amount of astrocytes fall off onto the bottom of the
well plates over the culture period for the co-culture samples. This approach is employed
to monitor the integrity of the in vitro models besides checking the tight junction
formation only.
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1.4 Summary
This study is about utilizing commercialized immortalized cell lines to build twocell-type co-culture in vitro BBB model, with the induction of aECM to induce better
endothelial brain like characteristics and functionality. There are ten chapters in this
dissertation, each with its specific focus.
Chapter II is the overview of the BBB. The chapter starts with the introductions of
the discovery history of BBB. How the barrier was initially discovered can be dated back
to more than one hundred years ago. Various studies by many different scientists have
been carried out in finding and confirming the existence of the BBB featuring brain
endothelial tight junction. How to distinguish between blood-brain barrier and bloodcerebral spinal fluid barrier is also described by schematic drawings. Followed by the
discovery history of the BBB, the most accepted BBB characteristics are introduced in
this chapter. Several key features and functionalities are discussed in depth with graph
demonstrations and list of tables. Anatomical physiology of the BBB is introduced later
in this chapter. The three-cell model including brain microvasculature endothelial cells,
astrocytes and pericytes is the current widely accepted BBB model. The functions and
contributions of each type of cell are introduced briefly in this chapter. In the end of the
chapter, several current drug delivery methods to the CNS are briefly discussed by
mechanisms, methods, applications, advantages and disadvantages.
Chapter III emphasizes on the contribution of astrocytes as one of the most
important building blocks of the BBB, and its role in the extracellular matrix is also
explored. A detailed description of how the acellular extracellular matrix derived from
astrocytes is introduced in this chapter too.
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Chapter IV starts with an elegant summary of the milestones in the history of
tissue and cell culture presented by MCBI’s knowledge base. With such necessary
background knowledge, the chapter then continues with the introduction of primary cells
and immortalized cell lines, respectively. Then the comparison of the advantages and
disadvantages between primary cell lines and immortalized cell lines are made, with
several issues being extensively discussed. The conclusions of why the author chose the
immortalized cell lines are made in the end of the chapter.
Chapter V focuses on the engineering of the in vitro BBB model. The chapter
begins with the introduction of several different BBB models attempts made in the earlier
ages, recent years and some unpopular ways. Each attempt is introduced by the type of
cells, setup method, evaluation methods and conclusions with the available information.
Discussions and comparisons of the advantages and disadvantages are briefly made. Then
as the major part of this chapter, detailed procedures of how the BBB in vitro co-culture
model is engineered are described. How to engineer astrocytes derived aECM is
introduced first. Scanning microscopy pictures of a confluent layer of astrocytes and
decellularized aECM are shown to distinguish these two very different layers. Optical
microscopy morphology pictures of cultured cells on the inserts as well as on the well
bottoms are shown. Each different sample setup is described and explained as well as the
engineering of the astrocytes derived aECM. A schematic drawing summarizing all the
different sample setups helps to better understand each model sample.
Chapter VI compares TEER values of different samples setups including “EC,”
“CO,” “CO+aECM” and some other setups for a total of 12 trials. The setups with
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consistent low TEER values will be excluded from further study since high TEER value
is one of the most important features of the BBB.
Chapter VII tests solute transport of several different compounds across the
sample membranes. The testing compounds include calcein, caffeine and DOX. The
measurement method is different from the most popular current radio-labeling methods
because of the limitations of the available facility on campus. The testing compounds
were dissolved by serum free media to reach suitable concentration readable for a
spectrophotometer in the UV-visible range. Thus optical absorbance was read by the
spectrophotometer, subsequently solute concentration and mass transport profiles are
calculated using optical absorbance vs. concentration calibration curve. Effective
permeability coefficients are calculated and transport profiles are compared and discussed
between different compounds as well as between different sample setups.
Chapter VIII examined the expression of Occludin, one of the earliest found tight
junction proteins using Western Blot and immuno-fluorescent microscopy. The western
blot focused on examining occludin expression level in astrocytes alone, EC alone, CO
and CO+aECM sample lysates, comparing with occludin positive sample. Immunofluorescent images are taken under a fluorescent microscope for co-culture samples
treated with antibodies that recognize occludin and conjugated with fluorescent dye.
Occludin contours and the density of tight junctions are compared and discussed in the
specific study. The study in the chapter further demonstrated CO+aECM samples is a
better setup in helping the endothelial cells better exhibit BBB like features such as tight
junction protein expression.
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Chapter IX shows a minor study examining the astrocytes cell loss from the basal
sides of the inserts from the co-culture samples by the SRB assay. The cell numbers were
determined by converting the optical absorbance value obtained from the micro plate
reader in the experiments using an experimentally obtained cell number calibration cruve.
Results showed that astrocytes cell loss from co-culture with aECM samples were much
less than those from the co-culture samples alone. The integrity of the BBB is partly
reflected in part by this study.
Chapter X is the conclusion chapter. The assumptions are testified throughout the
studies and the co-cultured BBB in vitro model with aECM is the optimal setup among
all the sample setups. Astrocytes derived aECM plays important role in the in vitro BBB
formation and the immortalized cell lines are approved to be practical in building the
BBB in vitro model.
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CHAPTER II OVERVIEW OF BLOOD-BRAIN BARRIER
2.1 The Discovery History of BBB
The brain functions within a well-controlled environment separate from the milieu
of the periphery. The mechanisms that control the unique environment of the brain are
collectively referred to as the "blood-brain barrier."
It has been over a century that the concept of BBB has been recognized for its
physiological existence. In the late 19th century, Paul Ehrlich, the German immunologist,
performed an experiment where water soluble dyes were intravenously administered(8).
As the result, it was found the body tissue as well as the choroid plexus were stained, but
the brain was failed to be stained, and the cerebrospinal fluid (CSF) had no color. It was
first thought the dyes did not have binding affinity to stain the brain. But later in the
beginning of the 20th century, Paul’s student, Edwin Goldman proved for the same dye to
stain the brain tissue but was not able to pass a certain barrier to reach into the brain. On
the other hand, another experiment where dyes were injected into the brain through
subarachnoid space showed instead the CSF was stained but not the peripheral tissues.
This also proved the existence of the ‘barrier.’ But, it was not until 1950 that Tschirgi
showed the main reason for the series dye experiments were the dyes bound to albumin,
the plasma protein, which was widely used in present studies as the agent to test the in
vitro BBB models.
It was in 1898 the blood-brain barrier was confirmed at the cerebral vessels level
by Bield and Kraus(9). They observed sodium ferro-cyanide or cholic acids had no
effects on the central nervous system (CNS) pharmacologically when injected
intravenously. But when the same agent was injected intraventricularly, the neurological
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symptoms occurred after the injection. In 1890, Lewandowsky was the first one to
introduce the term “blood-brain barrier” into the world.
Another series experiments were carried out by Goldman in 1909 and 1913 with
the Trypan blue injection in animals to further prove the existence of blood brain barrier.
The experiments also showed it was not because of the previous Ehrlich’s dyes’ binding
affinity that the brains were not stained. Trypan blue is a dye first synthesized by Ehrlich.
In the experiments, Trypan blue was injected to rabbits and dogs either through brain
ventricular system or intravenously. Likewise, the brain tissue was stained when Trypan
blue was injected through brain ventricular system, but, was colorless when the vital dye
was injected intravenously while the whole animal turned blue as well as the choroid
plexuses. Thus in 1913, Goldman introduced the hypothesis that the CSF was the vehicle
responsible for transporting substances. This theory was also recognized as “way of the
spinal fluid.”
Later in 1942, Friedemann found that lipid soluble dye was able to travel across
the cerebral microvasculature and stained the brain. Broman in 1941 introduced his
findings of two barrier systems in the brain: on at the choroid plexus called bloodcerebrospinal fluid and the other at the cerebral microvasculature called blood-brain
barrier(10). Figure 1 shows the schematic drawings of these two barriers. The blood-brain
barrier features continuous layer of endothelial cells connected by tight junctions as the
lining of capillaries, while the blood-cerebrospinal fluid barrier (BCSFB) is composed of
choroid plexuses and the arachnoid membranes of the circumventricular organs. The
barrier function of BCSFB is provided by the junctions between epithelial cells in the
choroid plexus which are slightly more permeable than those of the BBB. Broman later
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argued that the capillary endothelial cells while not the astrocytic endfeet should be
responsible for the blood-brain barrier function.

Figure 1 The schematic drawings of blood-brain barrier and blood-cerebral spinal
fluid barrier
Thanks to the development of high resolution electron microscopy, as well as the
sensitive tracer methods; the structural basis for the BBB was not cleared to the astrocytic
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and endothelial level until 1967. It was revealed by Reese and Karnovsky
ultrastructurally using electron-sense tracer horseradish peroxidase (HRP) showed that
endothelial cells in mouse cerebral capillaries formed a structural barrier to HRP, thus the
statement of BBB is “an endothelial barrier present in capillaries that course through the
brain” was made(11). Here HRP is a glycoprotein with a molecular weight of 39,800. It
can be cytochemically determined at both light and electron microscopic level. Reese and
Karnovsky found the HRP could travel through the first luminal inter-endothelial tight
junctions. The tight junctions are referred to as the junctions between the adjacent
endothelial cells in the blood-brain barrier, where the morphology appeared to be
continuous; pinocytotic vesicles could hardly be found and not engaged in the transport.
Other experiments with smaller protein tracers such as microperoxidase and ion
lanthanum were tested by intravenous injection by Feder in 1971 and Brightman and
Reese in 1969, respectively. All these experiments proved the tight junctions in BBB’s
ability to actively keep out specific substances from entering the brain interstitial fluid.
There have been extensive studies and controversial conclusions about the
development and maturation of BBB in vertebrates, from embryo to several days after
birth, and the data may vary between species. Since the study in this research will be
focusing on matured blood-brain barrier, the development or the maturation of the BBB
will not be further discussed in this chapter.
2.2 The BBB Physiology
2.2.1 The Gate-Keeping Barrier
William Pardridge has done extensive research in the BBB modeling area and in
his review in 2003; eloquent study has been carried out on the BBB’s impact in the CNS
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drug delivery(12). The BBB virtually restricts all molecules except the small and
lipophilic ones from entering the cerebral space. This is an important mechanism to
protect the brain by avoid the variation in plasma constitution. For instance, the internal
environment will not fluctuate much after meal, exercising and will not be disturbed too
much when the body intakes some certain neurotransmitters or xenobiotics(13). On the
other hand, to maintain an effective functional brain, some hydrophilic molecules such as
oxygen and carbon dioxide still can go through the barrier and enter the brain by active
transport where energy is required.
Only small lipophilic molecules with the molecular weight of 400-500 dalton
(some say 600) or under can across the BBB freely(14). But, the problem is that only a
few diseases, including epilepsy, depression and chronic pain, can benefit from the
aforementioned route utilizing small molecules(15, 16). Alzheimer disease, brain cancer,
stroke, HIV infection of the brain and many other brain related diseases are not treatable
by those small molecular weight medicines. According to Pardridge, no pharmaceutical
company has a drug-targeting program for the BBB(12). And there are certain limitations
that small molecular weight drugs cannot achieve in the CNS drug delivery. First of all,
there are only a few CNS diseases that response consistently to the lipophilic small
molecular weight drugs as aforementioned. And even for the drugs that are able to
permeate the BBB, the active percentages of these drugs are reported to be extremely low
in the CNS(17). Secondly, not all the small molecular weight drugs can effectively cross
the BBB to reach a pharmacological significant amount. Molecules that have too many
hydrogen-bond-forming groups, such as histamine, will have much difficult in crossing
the BBB because of its rate-limiting role(14).
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With the help of transport proteins, essential nutrients for the brain such as
glucose and some amino acids or related molecules are able to get into the brain by the
relatively high concentrations of those proteins in brain endothelial cells. Also, some
receptor mediated systems also exist on the BBB making it possible for some
macromolecules to enter the brain. Transferrin receptor, GLUT-1 glucose carrier and L1
amino acid transporter are among the best known ones(18, 19). However, large molecular
weight drugs for the CNS are not successfully developed because of the BBB. Even with
the existence of various transporting systems on the BBB, no such ‘transporter’ has been
found to be capable of effectively transporting larger molecules with small-molecule
peptidomimetic functioning as a endogenous ligand to the transporters, let alone all the
other larger molecular weight drugs, who are usual abandoned in the initial CNS drug
development studies.
P-glycoprotein is another transporter found on luminal endothelial membrane as
well as at astrocyte processes in the brains of both human and primate brains (20-22).
But, this membrane protein works on the opposite direction to the other membrane
proteins mentioned above. It basically expels a variety of substances out from the
cerebral space that penetrated into the brain. P-glycoprotein is an essential component of
the blood-brain barrier to maintain the homeostasis in the brain by keeping the potentially
toxic substances from accumulating in the brain, interfering brain’s normal function. Pglycoprotein is also the major protein expressed when evaluating the in vitro models of
blood-brain barrier(23).
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2.2.2 BBB Anatomical Features
As a complex environment, the BBB is composed of brain capillary endothelial
cells, astrocytes and pericytes(7, 24). Currently, the well-accepted blood-brain barrier is
the aforementioned three-cell model: brain micro vascular endothelial cells lining in the
cerebral space, together with the endfeet of astrocytes and pericytes to compose the
complete blood-brain barrier(25). Figure 2 gives a schematic view for both the BBB
three-cell model (A), as well as a traverse view showing how the brain capillary
endothelial cells lining together forming tight junction and how they interact with the
supporting astrocytes (B).

Figure 2 Illustrations of the BBB
2.2.2.1 Brain Capillary Endothelial Tight Junctions
The tight junctions in the BBB are characterized as the apical junctional complex
between brain microvascular endothelial cells(26). The junctions between the endothelial
cells in the brain capillaries are so tight that it is said to be on the 50~100 folds level than
peripheral vessels(27). The tight junctions greatly restrict the paracellular transport of
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water soluble substances so the transport is then mainly depended on transcellular
pathways as described in the previous section. Solute transport study of several different
molecules of various characteristics will be carried out for the in vitro model samples and
the results will be discussed in detailed in later chapters.
One of the best ways to reflect the tightness of the junctions is by measuring the
electrical resistance. Transendothelial electrical resistance (TEER) is the most widely
used parameter to describe the resistance in the barrier to validate the in vitro models.
TEER values measured in vivo can be as high as 2000
Ω cm

2

, while the values in

peripheral are only less than 100Ω cm 2. The TEER value measurement will be performed
to check all the in vitro samples as an indicator of the integrity of the samples. Detailed
procedure will be showed later in the method part.

Figure 3 Tight junction’s molecular components
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Table 1 Comparison between vasculatures between BBB and peripheral tissue
Property

BBB Vasculature

Peripheral Vasculature

Tight junctions

Present

Rare

Pincocytosis

Rare

Abundant

Fenestrae

Rare

Abundant

Electric resistance

High (~2000Ω cm2)

Low (<100Ω cm2)

Perivascular space

Small

Extensive

Alkaline phosphatase

Present

Absent

γ-glutamyl transpeptidase

Present

Absent

Monoamine oxidase

Present

Absent

Glucose transporter

Present

Absent

Cellular mitochondrial content

~10%

<5%

Receptor for transferrin & insulin

Present

absent

Several molecular components are unique to the tight junction, such as occludin,
claudins, ZO-1 and junctional adhesion molecules (JAMs) (26, 28). A schematic drawing
of the BBB tight-junction components is shown in Figure 3. Schematic drawing is
credited by Chiba et al.(34) Among these constituents of tight junction strands, occludin
was the first to be identified(29). It is an approximately 60 kDa transmembrane protein,
whose C-terminal region binds to ZO-1, which associates with actin cytoskeleton.
Several studies showed that occludin may be involved in signal transduction as signal
transmitter and thus an important component of the BBB (30-34). Western blot analysis
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and immuno-fluorescent study will be carried out to study the existence and expression
level of occludin on the in vitro model samples.
The blood-brain barrier vasculature is unique and distinctive in comparison with
the peripheral tissue vasculatures. Table 1 lists the comparison of some key features on
the vasculatures between BBB and peripheral tissues. The existences of tight junction and
membrane transporter proteins have been described in earlier sections. And because the
active transport are taking places more frequently than the peripheral tissues, more
cellular mitochondrial content is present to provide energy for such activities. High
electric resistance is another important characteristic to distinguish BBB from the
peripheral tissue vasculature, and this is also one of the numbers to evaluate the in vitro
BBB co-culture model. The anatomical BBB physiology is next topic to cover.
2.2.2.2 Roles of Astrocytes
A series of studies have implied that it is not intrinsic for brain microvascular
endothelial cells to demonstrate the BBB features. Rather, the CNS environment plays a
critical role inducing the cells with the properties(36). Astrocytes are among the most
recognized key components of the aforementioned environment. As early as in 1967,
Davson and Oldendorf predicted astrocytes to be the major source responsible for
inducing the BBB phenotype and specialization(37). Later studies proved the statement:
cultured astrocytes were found to induce the tightening of endothelial cells when planted
in the normal leaky sites(38). On the contrary, Stewart and Wiley found chick brain
endothelial cells on mesenchymal tissue implants from quail developed into leaky
capillaries(39). It was shown anatomically of the microvasculature in brain as in Figure 4
of how the astrocytes endfeet interact with endothelial cells(40). Rubin et al. suggested it
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is essential for the direct interaction between endothelial cells and astrocytes to build a
most favorable BBB(41). It is also the basis for this particular dissertation research of
astrocytes-endothelial cells co-culture systems.

Figure 4 The schematic drawing of interactions between astrocyte endfeet and brain
endothelial cells
Considerable efforts have been put into investigating the mediating agents to
induce and maintain the BBB phenotype and its characteristics. γ-GTP (gamma-glutamyl
transpeptidase) is a widely cited agent found on brain endothelium in situ responsible for
amino acid transport. It was found great amount of γ-GTP was lost from primary brain
endothelial cells shortly after they were isolated. The same thing happened to alkaline
phosphatase (ALP), which is responsible for removal of phosphate groups. Glut-1, Asystem and the L-system carriers are reported to be up-regulate on the brain endothelial
cells with the presence of astrocytic glial cells(22, 42). Transcytotic mechanisms for lowdensity lipoprotein (LDL) and expression of transferrin receptor are also reported to be
up-regulated by the influence of the astrocytes presence(43).
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Some in vitro systems utilizing non-brain sourced endothelial cells such as HUVEC-Cs from human umbilical vein and endothelial cells from bovine aorta have shown
BBB characteristics such as tight junctions or several specific markers(44). Even though
there exist some controversial arguments questioning astrocytes signaling and regulating
function, it is still widely testified and proved that astrocytes play important roles in
inducing and maintaining the development of the blood-brain barrier phenotype. It is also
considered the theoretical basis for this specific dissertation of the astrocytes-endothelial
cells co-culture system. But it is also suggested brain microvascular endothelial cells are
not the only cells responding to the signals of astrocytes.
2.2.2.3 Contribution of Pericytes
Pericytes are the cells shown in green in Figure 2 of the three-cell model. Clearly
the pericyte is separated by the basement membrane from the EC and the endfeet of
astrocytes. Morphologically, pericytes have round cell bodies, remarkable nucleus with
plentiful lysosomes and abundant cytoplasmic processes(45, 46). The origin of the word
‘pericyte’ gives a straightforward hint of the cell, from the location point of view: ‘peri-’
means around and ‘cyto-’ means cell (47).
Pericytes are believed to offer structural stability on vessel wall and
microvasculature vasodynamic capacities. It was observed on PDGF-B-deficient mice the
development of microaneurysm with the deficit of pericytes(48). Several other facts also
demonstrate the importance role of pericyte structurally maintaining the integrity of
microvessels: diabetic patients with pericyte metabolic injury are reported to have retina
microaneurysm formations(49); pericytes deterioration is found in cerebral hemorrhage
with amyloidosis hereditarily.
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CNS pericytes are considered as ‘housekeeping scavenger cells’(50-52). Some
studies have tried to show pericyte’s possible role in blood-brain barrier(50, 53, 54).
These studies provided evidence for the pericytes’ involvement structural integrity,
differentiation, angiogenesis regulation and genesis of blood-brain barrier. It was also
suggested pericytes may take part in neuroimmune functions when they exhibit
phagocytic activity.
Even though many mechanisms and implications of the CNS pericytes are still
elusive, they have proved themselves to take part in virtually all processes on the bloodbrain barrier. There has not been successful in vitro cell culture models reported to the
public. It will be very interesting to see a three-cell co-cultured in vitro model, which is
also much more close to the in vivo situation, but then the cell culture work will become
very complicated. It is still difficult to isolate CNS pericytes from primary culture, and
definitive cell markers remains hard to identify. With better understanding and technical
abilities, scientists will be able to investigate more on this important component of bloodbrain barrier.
2.3 Current CNS Drug Delivery Examples
The drug delivery routes to the brain are essentially to bypass the BBB. However,
current available methods are usually risky, highly invasive, can lead to irreversible side
effects or allow very limited distribution of drug within the brain tissue. Several most
popular methods are briefly introduced as follows.
Direct administration of drugs into the brain includes intracerebral administration
(ICA), intrathecal administration (ITA) and nasal administration (NA). Highly potent
therapeutic agents with highly restricted area of distribution are always administered via
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ICA. The advantage of this method is that a wide range of compounds in spite of their
sizes or formulations can be administered. However, this method is highly invasive,
which requires a hole drilled in the head but still with very limited brain distribution for
drugs of all sizes. ITA is often employed when local analgesia is needed. This method
injects or infuses small lipophilic drugs into the CSF surrounding the spinal cord. CNS
complications can almost always be avoided due to the rapid removal of these drugs from
CSF to systemic bloodstream. However, proteins administered this way have much
slower clearance rate from the CSF. Various compounds can be administered through
olfactory neural pathway directly to CNS by NA. This method is rapid yet non-invasive,
and does not need to modify the drugs or their carriers. Systemic side effects are also
eliminated. However, since NA requires small administration volume, sufficient drug
absorption amount is difficult to achieve.
BBB disruption can be achieved by modifications of tight junctions for
temporarily controlled and increased permeability of the brain capillaries. Injecting hyper
osmotic solutions such as mannitol can temporarily pull apart tight junctions due to
shrinkage of cerebral endothelial cells and expansion of blood volume. Paracellular
diffusion of hydrophilic compounds is enhanced by this method. One noticeable
drawback is beta-galactosidase over expression due to this method.
BBB permeability can also be achieved in a concentration- and time-dependent
disruption manner. Endogenous proinflammatory vasoactive agents such as histamine,
bradykinin, and nitric oxide can all be employed by this method. However, the limitations
are rather obvious: the method is very short-acting, has a narrow therapeutic window and
also has significant dose-limiting side effects. Because of these limitations, analogs of
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these endogenous proinflammatory vasoactive agents are being studied and developed to
facilitate better BBB disruption while reducing the side effects. However, there is still a
long way to go on this route.
2.4 Summary
This chapter introduces the basic biology of the BBB, including the most popular
three-cell model, and supporting introduction of the contributions of the three types of
cells. The three types of cell are defined one by one in the order of endothelial cells,
astrocytes and pericytes. Endothelial tight junction and tight junction proteins are
introduced in the endothelial cells section. Astrocytes’ role in inducing endothelial cells
brain-like features are briefly mentioned in this chapter but will be explained in extended
detail in the next chapter. The contributions of pericytes as the essential building block of
BBB are also explained. Current CNS drug delivery methods have also been discussed in
the end of the chapter.
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CHAPTER III ASTROCYTES AND EXTRACELLULAR MATRIX
3.1 Astrocytes’ Development and Morphologies
Astrocyte is a type of glial cell which possess star-shaped morphology and glial
fibrials as intermediate filaments. Copious extended astrocytic processes surround
adjacent blood vessels and neural cells. However, it is not easy task to define astrocytes
as will do for most other types of cells(55). The now widely-accepted concept is that
astrocytes stand for a various population of cells with plentiful of functions.
Characteristics of astrocytes are briefly summarized in following paragraphs for better
understanding the definition of this special type of cell.
In mammals, astrocytes are found to be derived from various lineages, suggesting
that astrocytes are created from different manners, which explains the diversity of
astrocytes even in the same region of the brain(56, 57). For examples, grey matter
astrocytes (protoplasmic astrocytes) are generated from embryonic radial glia, while
white matter astrocytes (fibrous astrocytes) are generated from neonatal SVZ progenitors.
Cai et al. performed a study on the astrocytes diversity in 2007 where they found out the
grey matter astrocytes up-regulated GFAP in the absence of Olig2, while the formation of
white matter astrocytes was greatly affected(58).
The morphology of astrocytes is heterogeneous and very complex. Astrocytes
were originally named after their star-like shape morphology as depicted in Figure 5
demonstrated by Wang et al. (27). Astrocytes are recognized as “process-bearing cells”
that exist throughout the nervous system but they do not possess dendrites or axons.
However, astrocytes are heterogeneous as previously mentioned. For example, grey
matter astrocytes have numerous branching processes, providing sheath to synapses and

24

covering to the blood vessels with their endfeet. White matter astrocytes’ processes are
long, thin and unbranched. The endfeet of white matter astrocytes wrap nodes of Ranvier.
The astrocytes that form BBB are known as “pituitary astrocytes pituicyte”. These
astrocytes’ morphology presents certain polarity as Figure 6 shows.

Figure 5 Morphology of an astrocyte, which shows a typical star-like morphology
Even though astrocytes are diversified based on their different antigenic and
morphological features, they do share many general biophysical properties which led to
the initial conclusion that astrocytes are “passive cells”(59). These biophysical properties
are known by examples as: astrocytes’ hyperpolarized resting membrane potentials (-80
or -90 mV); under physiological conditions astrocytes do not generate action potentials;
and large voltage-independent K+ currents exist in astrocytes, which include cases when
voltage-dependent K+ currents are presented(60). However, the word “passive” is no
longer being used with the advances of the astrocytes research. Controversies in the
understanding of astrocytes still exist largely in the neural science research world and lots
of further studies will have to be carried out to give us even better understanding of the
astrocytes biophysical characteristics.
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Figure 6 Morphology of astrocyte in the BBB, with certain polarity
3.2 Astrocytes’ Functions
Astrocytes are known to express a large amount of receptors important in
regulating self development as well as in responding to neurons and injuries(61, 62). The
receptors expressed by astrocytes include ionotropic receptors, G-protein coupled
receptors, receptors for chemokines, steroids, growth factors, and receptors related to
innate immunity(63, 64).
One of the most noticeable astrocytes receptor expression characteristics is,
cultured astrocytes are known to express nearly all the receptors exists in neurons as
found when astrocytes are subject to acute slices or in vivo. This characteristic is very
important especially in BBB co-culture modeling, making it possible for the in vitro BBB
model to possess similar feature to mimic the in vivo situations. However, exceptions are
not extinct for some cases, but the rare receptor express cases in astrocytes are not typical
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and of little importance in the BBB in vitro modeling assessment(65, 66). Astrocytes are
also shown to adjust their receptor expression in accordance to their surrounding
environment. Various receptors in different amount will be triggered to be expressed due
to the change of environment such as in case of brain injury(67).
Well accepted astrocytes functions include BBB induction and maintenance,
synthesizing adhesion molecules, extracellular matrix proteins, extracellular K+
buffering, metabolic support, angiogenesis, detoxification, immune functions, and many
other functions. Actually, astrocytes are considered the major producer of adhesion
molecules in the central nervous system (CNS). Evidence has shown that integrin matrix
adhesion receptors secreted by brain astrocytes and endothelial cells are important in
maintaining BBB permeability which will be discussed in more detail in next section(68,
69).
Because of the topic of this specific dissertation, astrocytes function in BBB
induction and maintenance, and its function in extracellular matrix protein synthesis will
be the discussion focus in following sections.
3.3 BBB Induction and Maintenance
As previously mentioned, brain capillary endothelial cells are enveloped by
astrocytes endfeet – specialized processes sent by astrocytes, where they form rosette-like
structures(40). Moreover, astrocytes are believed to induce and regulate the BBB, more
specifically, the formation of endothelial tight junction and transport systems
expression(19, 26).
Numerous reviews have shown that by co-culturing with astrocytes, tight junction
proteins in brain endothelial cells isolated from the brain are up-regulated, thus able to
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maintain most of the BBB phenotype and characteristics(70, 71). Otherwise, if the
isolated brain endothelial cells are cultured alone, certain BBB features will be lost(72).
The aforementioned proteins being up-regulated in the existence of astrocytes are but not
limited to GLUT1, P-glycoprotein, the L- and A- system amino acid carriers(42). These
proteins are mentioned in previous chapters as important factors in the BBB
characteristics.
Furthermore, studies found out that culture media taken from astrocytes overexpressing SSeCKS, known as conditioned media, helped to block angiogenesis both in
vitro and in vivo. Such media also showed the ability to help increase tight junction
proteins in cultured endothelial cells, thus reducing permeability to certain solute
transport. Astrocytes are also believed to involve in the maintenance of BBB for its tight
junction and microvascular permeability. Thus it is safe to conclude it will be beneficial
to include astrocytes as a component of the in vitro BBB model to provide the endothelial
cells brain like feature induction.
Last but not least, the BBB induction and maintenance is not a one-way street.
Cultured astrocytes growth is also found to be reciprocally influenced by endothelial
cells(73). Laminin production, glutamate synthetase activity and antioxidant enzyme
activity are all proved to be regulated in such reciprocal way.
3.4 Secretion of Extracellular Components
In the CNS, astrocytes are the major cell in charge of secreting cell adhesion
molecules (CAM) and extracellular matrix (ECM) proteins. Various studies have shown
astrocytes’ ability to regulate neurite growth by regulating the expression of certain
molecules in response to in vitro environmental changes. Some of these molecules are
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Laminin, N-cadherin, fibronectin and neural CAM(74-76). Astrocytes are also reported to
be involved in ECM degradation and remodeling by playing fundamental role by
producing proteolytic enzymes, particularly matrix metalloproteinases(77-79).
Astrocytes are known to regulate neuronal maturation and survival by discharging
growth factors such as fibroblast growth factor (FGF), brain-derived neurotrophic factor
(BDNF), nerve growth factor (NGF), and etc(80). Cultured astrocytes are also capable of
releasing growth factors in vitro. For example, neuronal survival and neuronal growth
induction are enhanced by cilliary neurotrophic factor (CNTF) secreted by astrocytes,
probably through a Ca2+ dependent pathway. Astrocytes can also release other molecules
such as S100B to promote neurite outgrowth and astrocytic glutamate uptake in case of
injury.
More recent researches keep finding out more and more astrocytes’ involvement
in ECM secretion such as its role to promote synaptogenesis between developmental
CNS neurons in vivo and in vitro. The goal of research is to investigate the possibility to
use astrocytes derived acellular-ECM (aECM) in the in vitro co-culture model building in
order to help maintain the BBB properties of the co-cultured endothelial cells, and to
increase the quality of the in vitro BBB system. The aECM is a piece of layers derived
from confluent astrocytes in vitro culture where cells are lysed and washed away and
only the astrocytes skeleton and the extracellular components are left for endothelial
seeding. The procedures will be described in more detail in the methodology part.
3.5 Summary
This chapter focuses on introducing the astrocytes by study their development,
morphology and functionalities. It is important to understand astrocytes’ role in BBB
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induction and maintenance, which will be the theoretical support of building the in vitro
model as a co-cultured system. Astrocytes’ important role in ECM component secretion
is also vital and gives the author inspiration of the novel approach where astrocytes
derived aECM are introduced in engineering the co-culture BBB in vitro model. Move
onto next chapter, the application of primary cells versus immortalized cell lines are
going to be discussed and compared.
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CHAPTER IV PRIMARY VERSUS IMMORTALIZED CELL LINES
4.1 Noticeable Marks during Tissue Culture Development
Animal sourced cells have a long history of being used in scientific studies, being
in vitro cultured since around 1900s. Cells for in vitro studies are majorly divided into
two categories: primary cells that are derived directly from animal tissues, or
immortalized cell lines specially treated that are able to be subcultured to an extensive
passage number and utilized as cell banks(81). However, before introducing either of the
cell lines, some noticeable events/discoveries in the development history of the tissue and
cell culture should be acknowledged and appreciated in the following table summarized
and presented by NCBI (Copyright © 2002, Bruce Alberts, Alexander Johnson, Julian
Lewis, Martin Raff, Keith Roberts, and Peter Walter; Copyright © 1983, 1989, 1994,
Bruce Alberts, Dennis Bray, Julian Lewis, Martin Raff, Keith Roberts, and James D.
Watson.).
Table 2 Noticeable events/discoveries in the development history of the tissue and
cell culture
1885

1907

1910

“Roux shows that embryonic chick cells can be maintained alive in a saline
solution outside the animal body.”
“Harrison cultivates amphibian spinal cord in a lymph clot, thereby
demonstrating that axons are produced as extensions of single nerve cells.”
“Rous induces a tumor by using a filtered extract of chicken tumor cells, later
shown to contain an RNA virus (Rous sarcoma virus).”

1913 “Carrel shows that cells can grow for long periods in culture provided they are
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fed regularly under aseptic conditions.”
1948

1952

1954

“Earle and colleagues isolate single cells of the L cell line and show that they
form clones of cells in tissue culture.”
“Gey and colleagues establish a continuous line of cells derived from a human
cervical carcinoma, which later become the well-known HeLa cell line.”
“Levi-Montalcini and associates show that nerve growth factor (NGF) stimulates
the growth of axons in tissue culture.”
“Eagle makes the first systematic investigation of the essential nutritional

1955

requirements of cells in culture and finds that animal cells can propagate in a
defined mixture of small molecules supplemented with a small proportion of
serum proteins.”

1956

“Puck and associates select mutants with altered growth requirements from
cultures of HeLa cells.”
“Temin and Rubin develop a quantitative assay for the infection of chick cells in

1958

culture by purified Rous sarcoma virus. In the following decade the characteristics
of this and other types of viral transformation are established by Stoker,
Dulbecco, Green, and other virologists.”

1961

“Hayflick and Moorhead show that human fibroblasts die after a finite number
of divisions in culture.”
“Littlefield introduces HAT medium for the selective growth of somatic cell

1964 hybrids. Together with the technique of cell fusion, this makes somatic-cell
genetics accessible.”
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“Ham introduces a defined, serum-free medium able to support the clonal growth
1965

of certain mammalian cells.”
“Harris and Watkins produce the first heterocaryons of mammalian cells by the
virus-induced fusion of human and mouse cells.”
“Augusti-Tocco and Sato adapt a mouse nerve cell tumor (neuroblastoma) to

1968

tissue culture and isolate clones that are electrically excitable and that extend
nerve processes. A number of other differentiated cell lines are isolated at about
this time, including skeletal muscle and liver cell lines.”

1975

“Köhler and Milstein produce the first monoclonal antibody-secreting
hybridoma cell lines.”
“Sato and associates publish the first of a series of papers showing that different

1976 cell lines require different mixtures of hormones and growth factors to grow in
serum-free medium.”
“Wigler and Axel and their associates develop an efficient method for
1977 introducing single-copy mammalian genes into cultured cells, adapting an earlier
method developed by Graham and van der Eb.”
1986

1998

“Martin and Evans and colleagues isolate and culture pluripotent embryonic
stem cells from mouse.”
“Thomson and Gearhart and their associates isolate human embryonic stem
cells.”
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4.2 Primary Cells
Primary cells are one of the most popular choices in the in vitro studies that find a
wide range of applications in various scientific disciplines. A brief summarizing
description of how to isolate cells for primary cell culture of rat brain endothelial cells is
described in following paragraphs(82, 83).
First, in the preparation stage, a suitable tissue culture flask needs to be coated
with type I collagen and kept at 4ºC overnight. After drying in the 37 ºC incubator, the
flask will be stored in the 4 ºC fridge until use. Several different solutions will be used in
the isolation procedure alone. The growth medium needs to be supplemented with
various ingredients for different purposes which will be revealed in the following
descriptions.
With the available appropriately euthanized rat, careful surgery procedures are
applied to aseptically remove the rat brain hemispheres from the skull which will be put
in PBS. Blood vessels and meninges need to be carefully removed and discarded. Then
chop the brain tissue into tiny pieces using scalpels under sterile conditions. The minced
brain tissue will then be put in centrifuge tubes containing 0.5% Dispase and incubate at
37ºC for 3 hours in a shaking bath with 100-120 rpm. The mixture will be subject to
centrifugation at 1000g for 10 minutes, after which the pellets at the bottom will be
collected and transferred to plastic bottles containing 15% Dextran in growth medium.
This mixture will undergo further centrifugation at 5800g for 10 minutes to separate the
microvessel from other tissue elements. The pellets were rinsed by growth medium and
collected by another centrifugation. Further incubation of the collected pellets containing
microvessel in growth medium and 5% serum containing 1mg/ml collagenase/dispase in
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a 100 rpm shaking water bath for 14-16 at 37ºC will help to remove the basement
membranes and pericytes. This mixture will undergo centrifugation for 6 minutes at
800g, followed by rinsing with growth medium and 5% serum. Another centrifugation
under of 6 minutes at 800g will result in the pellet ready for next step.
The pellet solution from last step will be added onto Percoll gradient solution
containing 50% Percoll in growth medium in a centrifuge tube. Centrifuge this mixture
for 10 minutes at 1000g will separate the endothelial cells from cellular debris and red
blood cells. Then the pellets will be resuspended with growth medium and 10% serum
and centrifugation will be repeated to remove further impurities. The final density of the
resuspended pellet should be controlled at around 1.055g/ml of cell mixtures in growth
medium and 10% serum. The cell number can be determined by hemacytometer counting
under an optical microscope. According to the protocol, 2-4g surgically obtained brain
tissue can yield approximately 0.4-0.7×106 cells. Part of the obtained cells can be seeded
on the collagen coated flask at the density of 0.5×106 cells/cm2 and maintain growing.
Rest of the cells can be cryo-preserved in liquid nitrogen for future use.
In the very initial stage of the dissertation, several trials of isolating rat brain
endothelial cells were attempted. However, due to the complication of available
experiment facility, as well as the limited supply of animal sources, the author was not
able to successfully obtain enough amounts of isolated rat brain endothelial cells
sufficient for the study. A real lab picture demonstrating the obtaining of rat brain is
shown below. The bulging eyes of the rat were like a silent accusation which arouses
another important ethical issue why the author was determined to use immortalized cell
lines in her study. The reason will be briefly discussed in later sections.
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Figure 7 Dissecting rat for its brain hemispheres
4.3 Immortalized Cell Lines
It is not an easy task to obtain and maintain primary cells cultures, even after all
those time and money consuming procedures described in the previous section.
According to Dorovini-Zis et al., primary human brain endothelial cell culture generally
will lose BBB characteristics after only after passages. While on the other hand,
immortalized cell lines are able to retain certain level physiological and morphological of
the BBB characteristics. And the best part is, unlike primary cell lines, immortalized cell
lines are able to proliferate through an extended number of passages without going into
senescence. Nowadays, biological companies are able to provide researchers with
abundant ready to use high quality immortalized cell lines at relatively low prices.
Immortalized cell lines are becoming more and more important yet convenient tool in cell
and tissue studies.
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Immortalized cell lines are initially obtained from isolating desired cells from
animal sources. However, a procedure altered these cells which made them virtually
escape the cell fates and that why they are called immortalized cells. The underlying
theoretical basis to immortalize cells is through expression of the telomerase reverse
transcriptase protein, particularly those cells most affected by telomere length. This
protein is inactive in most somatic cells, but when it is exogenously expressed the cells
are able to maintain telomere lengths sufficient to avoid replicative senescence. The most
popular method to alter cells is known as viral transformation. Viral genes such as
adenovirus E1A and E1B, human pappiloma virus (HPV) E6 and E7, Simian virus 40
(SV 40) and Epstein-Barr virus (EBV) are among the popular ones to be used in to
immortalize cells by viral transformation.
The immortalization procedure is a fairly simply procedure, and best of all, this
procedure is usually accomplished by the cell vendors but not the researchers. Thus by
purchasing the already immortalized cell lines, researchers are able to obtain
“standardized” cells that can be passed on for an extensive number of passages which
helps to save both time and money.
4.4 Choice between Primary and Immortalized Cell Lines
As previously introduced, co-culture systems with endothelial cells and astrocytes
are by far the most widely used in vitro BBB modeling methods for drug delivery
studies(6). Different cell lines including bovine brain endothelial cells, human primary
brain endothelial cells, MDCK cells lines, and caco-2 cell lines have been used in the
existing in vitro BBB models(7). However, most of the current successful BBB in vitro
models are based on primary cell cultures.

37

The reason for choosing primary cell cultures is mainly because of their relatively
high correlations with in vivo models in terms of high TEER values and tight junction
proteins expression. However, the seemingly high correlation inevitably diminishes
within several passages of initial cultures(28). Besides, the availability of the primary
cells can be limited for primary cultures because of the accessibility of the animals.
Pathogens and donor-to-donor variability account for other major drawbacks of primary
cell culture(28, 84). The repeatability and consistency of the in vitro models are thus
unappealing. Last but not least, with the rising awareness of animal rights, researchers are
facing an important ethical issue of repeatedly sacrificing animals for cells.
Unfortunately, because of the nature of the primary cells, numerous animals will have to
be sacrificed to meet the demand of new and more cells. The author herself volunteers in
an animal shelter and is reluctant to use animal as she believes animals and mans are
created equal; animals should not be sacrificed unlimitedly for the mere benefit of
human. With this in mind, commercially available immortalized cell lines can be
considered as an alternative.
Several advantages of using commercially available immortalized cell lines are: 1.
reliability: cells can be purchased from trusted well-established sources; 2. consistency
and reproducibility: the variance between different trials of experiments can be
minimized since the cell source is controlled and consistent; 3. longevity: immortalized
cell lines are specially treated by a transfection process so that the important cell features
can be maintained in a prolonged period of time(85); 4. accessibility: cells are available
to be purchased at any time, waiting time for the cell source can be confidently
diminished; 5. efficiency: preparation time and cost are reduced because the cells can be
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immediately used upon purchase; 6. ethically: yes animals will be sacrificed for their
cells, but since the immortalized cells can be reproduced and cryo-preserved in large
quantity for an extended time period without going into senescence, the number of
sacrificed animals is significantly reduced in comparison to those primary culture
methods that demands new cells every several weeks.
For example, in this particular study, the authors purchased both cell lines from
ATCC with the total price of under $500. Upon receiving, the cells were cultured in
appropriate ways to expand the numbers and most of them were later cryo-preserved for
future use. The cells used in the assessment were from passage 2 to passage 10. No
significant difference was observed between samples made from different passages of the
cells, thus the consistency of the in vitro samples was made possible. If the authors chose
to use immortalized animals, for each type of the cell, 2 to 3 days would have to be
dedicated into cell isolation. The cost for all the various chemicals may add up to several
hundred dollars. Rat would be a favorable choice of animal since they are relatively
easier to obtain and lower costly, but each rat can still cost from $20 to nearly $100, let
alone the special trained personnel needed to handle the animal. Even if the primary cells
were successfully isolated and expanded, another animal will have to be sacrificed before
the passage number reach 10. There could be variance between each passage, and also
between animals. The efficiency difference between primary cells and immortalized cell
lines is apparent. To the author’s best knowledge, no group has reported successful
results from in vitro BBB models with aECM using commercially available immortalized
cell lines. It will be very interesting to see how the results in this dissertation compared to
traditional in vitro models.
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4.5 Summary
This short chapter starts with the introduction of noticeable events/discoveries in
the cell and tissue culture history that every tissue engineer should come to acknowledge
and appreciate. The table presented by NCBI summarizes the milestones in the tissue
engineering history, which helps the author better understand and more proper handling
of tissue culture experiments nowadays. After that, primary and immortalized cell
cultures are introduced with an example of how to obtain and isolate primary cells from
an animal. Then at the end of the chapter, the comparisons between these two cell culture
methods are made and author’s decision and reasoning are stated.
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CHAPTER V ENGINEERING IN VITRO BBB MODEL
5.1 Existing BBB in vitro Models
5.1.1 Early Attempts
Primary cultures were the main focus in the earlier attempt on a blood-brain
barrier in vitro model. Endothelial cells isolated from porcine, bovine and rodent brains
were established into in vitro cultures. The main reason for setting up those systems was
to test in vitro how well the drugs can penetrate through the barrier since in vivo test was
difficult to perform. As the result, the systems did show some transport properties close
to the real cases, and junctions were formed. But the TEER values were not high at all
falling in the range of around 10Ω cm 2 which is similar from the endothelial cells from
aorta. The results were not surprising, but they were clearly not too successful as an in
vitro model for valid tests.
Other early attempts have been focusing on testing and understanding the
properties of the endothelial cells and capillaries on blood-brain barrier in vitro. Thus a
system very similar to the brain needed to be derived. Scientists have tried on endothelial
cells isolated from porcine, rodent and even human brain tissues. Some of the data or
results discussed on the BBB features are thanked to those experiments.
5.1.2 Current Attempts
It has been mentioned in previous chapters that the current most popular method is
to establish the in vitro BBB models with the presence of astrocytes trying to adjust the
culturing environment to be more like in the brain. Numerous studies have been carried
out by various groups of scientists, and some did show promising results on several of the
BBB features including tight junction, high resistance, as well as the expression of some
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BBB definitive substances such as the expression of P-glycoprotein. Some examples
reviewed and reproduced by Garberg et al.(7) are briefly introduced in the next section.
5.1.2.1 Primary Bovine Brain Endothelial Cells (BBEC)
This was not a real co-culture case. Primary BBECs (from passage 4-7) were
cultured on the upper side of a cell culture insert (Millicell PC 3 µm pore size, 30mm
diameter, by MIllicell Corporation Bedford, MA 01730) with primary rat astrocytes
cultured on the bottom of the same well where the insert was. The media for the coculture system was conditioned and modified for both cells’ optimal growth. The
endothelial cells layer formed in 7 days. This model showed high TEER value (500-800Ω
cm2) with comparably low permeability to two tested markers: sucrose (4.0*10-6 cm/s)
and insulin (0.7*10-6 cm/s).
5.1.2.2 Primary Human Brain Endothelial Cells (HPBEC)
This is a co-cultured in vitro model where astrocytes were plated on collagen
coated TranswellR inserts (0.4µm pore size, 12mm diameter by Costar) until reaching
confluency, followed by endothelial cells plating on the other side. Primary HPBEC were
established from adult human normal tissue and primary astrocytes were from normal
human cerebral tissue. The endothelial cells layer formed in 15 days. A series of transport
tests of various agents were performed on this co-culture model. However, the results did
not succeed in telling apart between transport mechanisms between passive transport and
carrier mediated transport or active transport.
5.1.2.3 Immortalized Rat Brain Endothelial Cells (SV-ARBEC)
The SV-transfected immortalized ARBECs were cultured with conditioned media
by SV-transfected immortalized neonatal rat astrocytes. The culture vessel was collagen
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coated cell inserts (1µm pore size, 0.83cm2 growth area by Falcon). The researchers
established the immortalized cell lines by SV-transfection, a popular way for
immortalization. After lengthy transfection procedures, SV-ARBECs from passage 80-90
and SV-astrocytes from passage 75-85 were used in this study. The astrocytes
conditioned media were collected after 4 days from an 80% confluent astrocytes culture.
However, the results of transport study were confusing. For example, instead of being
influxed, some testing compounds were found to be effluxed by the in vitro model. And
for small molecules such as caffeine, carrier mediated transport were found to be more
dominant than passive transport, which was controversy to the theories. What’s more, it
was impossible to find the correlation between in vivo and in vitro permeability
coefficients.
5.1.2. 4 Immortalized Mouse Brain Endothelial Cells (MBEC4)
This is not a co-culture system: the authors immortalized MBEC4s by SV 40 and
then cultured the cells by themselves on TranswellR cell culture inserts (0.4µm pore size,
for 12-well plates). The transport study was conducted 40 hours after the monolayer
seeding, and TEER measurement took place just 30 minutes after the cells were seeded.
Transport polarity on the membrane when tested from basolateral to apical and apical to
basolateral was not distinguished. Not too many valuable data was observed from this
model. Similar as for SV-ARBEC the case, not surprisingly, in vivo and in vitro
permeability coefficients were also low.
5.1.2.5 Madin-Darby Canine Kidney Cell Lines(MDCK)
MDCK have been reported as blood-brain barrier models(86). In this, three
MDCK cell lines were studied: one cell line was immortalized MDCK purchased from
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ATCC, and the other two were provided by Netherlands Cancer Institutes. The MDCKs
were cultured on TranswellR cell culture inserts (0.4µm pore size, 12mm diameter, by
Costar, Cambridge, UK) growing with media with necessary supplements but not
conditioned by astrocytes. TEER values were carried out by a “chopstick electrode” (by
Millicell ERS, Millipore, Oslo, Norway). MDCK from ATCC (from passage 59-63) had
TEER value measured at about 300
Ω cm

2

. And it did show some ability in detecting

passively distributed substance during the study. TEER values for the other two MDCK
cell lines (from passages 8-23) were even lower than MDCK from ATCC. But they also
did show the ability in distinguishing compounds for passive transport and know efflux
substrate.
5.1.2.6 ECV304 Cell Line
Previous research reported ECV304s were used for feasible immortalized bloodbrain barrier models(44, 87, 88). In this study, scientists used immortalized ECV304 and
rat glioma (C6) both purchased from European Collection of Animal Cell Cultures
(ECACC). CellagenTM membrane culture inserts were used in this experiment. ECV304
cells were cultured on the upper side of the inserts, and C6 glioma cells were cultured on
the other side of the inserts. Confluent endothelial cells layers were achieved after 3-4
days of initial plating. The highest TEER values at around 100Ω cm

2

were observed at

within 5-6 after endothelial cells were seeded. Relatively high correlation between in vivo
and in vitro permeability was reported from this model.
5.1.2.7 Human Colon Adenoma Derived Cell Line (Caco-2)
Caco-2 cell line has become a very good example predicting intestinal
absorption(89). Yee and Artursson et al. reported correlation the Caco-2 cell line with in
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vivo absorption in human(90, 91). But it may not be an ideal cell line in prediction of
blood-brain barrier tight junction(92). In the author’s study, the immortalized Caco-2 cell
line was purchased from ATCC. They were cultured on a TranswellR insert’s (0.4µm
pore size, 12mm diameter) upper side. Transport studies were carried out within 14-28
after the cells were seeded. TEER values were carried out by using a “chopstick
electrode” (by Millicell ERS, Millipore, Oslo, Norway). Actually, this is not a real bloodbrain barrier model. Rather, it should be called a research focusing on monolayer’s
transport properties. However, the test results showed relatively high TEER value
(>600Ω cm2) for this cell line and low permeability for some of the testing compound.
But the in vivo and in vitro are still reported to be poorly correlated.
5.1.3 Other Approaches
Scientists have also tried alternative measures by directly using approved factors
to induce endothelial tight junctions and BBB characteristics in the in vitro models. It
was reported by Rubin et al. in 1991 that the endothelial tight junction and resistance
showed remarkable increment with raised level of cyclic adenosine monophosphate
(cAMP)(93). Several other researchers have reported similar results using the same
method(70, 94, 95). This endeavor has provided optional route building the endothelium
alone. But the ultimate goal in this specific dissertation will be to establish and mimic a
system actually close to the real brain, so the endothelial cells alone will not be sufficient
enough. Furthermore, another important aspect of the particular study will be to evaluate
the efficacy of using commercially available immortalized cell lines to improve
efficiency of the modeling work. Thus a co-culture in vitro model built from purchased
cell lines with the addition of astrocytes derived aECM will be the focus of study.
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5.2 Materials and Reagents
5.2.1 Choice of Cell Lines
In this study, two immortalized cell lines purchased from American Type Culture
Company (ATCC, Manassas, VA) are employed in the in vitro co-culture system. They
are mus musculus (mouse) endothelial cells (CRL-2583) and Rattus norvegicus (rat)
astrocytes (CRL-2006). Brief introduction of the cell lines by ATCC is as following
paragraphs show.
The C166 cell line was established from cells from a 12-day F1 embryos obtained
by mating a female NMRI/GSF mouse with a male CD-1 mouse that was transgenic for
the human fes (fps/fes) proto-oncogene. C166 cells exhibit normal endothelial
characteristics, such as rearrangement into tube like structures when placed on Matrigel®
and retention of cobblestone morphology at confluence. The cell line was reported with
capability to support the stable proliferation of multipotent hematopoietic stem cells, thus
generating adequate numbers of cells for study of the mechanisms involved in their
subsequent development and differentiation. The CRL-2583 cell line which will be
actually used in the study was derived from the C166 cell line by transfection with a
plasmid reporter vector, pEGFP-N1, encoding enhanced green fluorescent protein (GFP).
Type 1 rat astrocytes/glial cells have been reported to successfully inducing
various sourced endothelial cells some of the blood-brain barrier phenotype and
characteristics by researchers. The CRL-2006 cell line used in this study was established
from primary cultures of type 1 astrocytes from brain frontal cortex tissue of 1 day old
rats. The cells are reported to retain characteristics consistent with the phenotype of type
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1 astrocytes. About 20% of the cells have glial fibrillary acidic protein (GFAP) immunoreactivity.
Another relevant reason to choose these two specific cell lines is because they are
both recommended by ATCC to grow in the same type of medium. Thus the time of
handling and complexity of the experiment can be further reduced. Because if in the coculture, the two types of cell lines require different media, usually media conditioning
will be required to finally find a optimal media mix ratio for the health of both of the cell
lines, which can take more than one month and more than 5 passages to accomplish.
5.2.2 Choice of Culture Vessels
1) BDTM Falcon canted neck tissue culture flasks with filter caps: major culture
vessel to proliferate cells in order to provide enough number of cells for further study.
Two different sizes 25cm2 and 75cm2 satisfy the demands of cell numbers. The canted
neck with filter caps help to reduce contamination during handling.
2) Corning Costar® Collagen I & III coated (COL) TranswellR inserts for 24-well
plates: major cell culture vessels for building co-culture system. The two types of cells
will be seeded on the two sides of the insert, respectively. The inserts feature
polytetrafluoroethylene (PTFE, commercial name: Teflon) membrane coated with rat tail
collagen I & III with 0.4µm pore size ideal for co-culturing.
3) Corning Costar® TranswellR inserts for 24-well plates: cell culture vessels for
building co-culture system alongside the COL inserts. These inserts have similar
specifications as for the COL inserts expect for the membrane material and collagen
coating. Table 3 shows some most important specification of the two types of inserts.
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Table 3 Specifications of Corning Costar® TranswellR inserts for 24-well plates
Insert type

COL Transwell

Normal Transwell

Insert membrane material

PTFE

Polycarbonate

Coating

Type I & III collagen None

Optical property

Clear when wet

Translucent

Cell visibility

Cell outlines

Poor

Pore size (µm)

0.4

0.4

Insert diameter (mm)

6.5

6.5

Insert Growth area (mm2)

0.33

0.33

Media volume (µl/well)

600

600

Seeding density (cells/well)

30000

30000

Media volume (µl/insert)

100

100

Seeding density (cells/insert) 5000

5000

4) Corning Costar® multi-well plates: major cell culture vessels for testing, where
the inserts are placed. The 24-well plates are the major vessel in the co-culture model
building to host the inserts. While the 12-well plates are used to produce astrocytes
derived aECMs.
5) NalgeneTM Cryogenic vials: major vessel to preserve excessive cells in liquid
nitrogen vapor phase for further use. The 1.5ml volume is suitable for the cryopreservation system in the current lab.
6) Corning Pyrex Brand Crystallizing Dishes: it is a special tool to be use to host
the inverted culture inserts to allow cells grow on the bottom side of the inserts. The
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specific model has a height of 1.96 inch, high enough for the inverted inserts to be totally
submerged while still having enough space on top of the inserts to hold the media. More
details about this deep dish will be introduced in the sample setup section.
5.2.3 Media and Other Major Reagents
1) Dulbecco’s Modified Eagle’s Medium (DMEM) from ATCC: it is the
recommended cell culture media for both cell lines in this study. The medium contains
4mM L-glutamine, 4500mg/L glucose, 1mM sodium pyruvate, and 1500mg/L sodium
bicarbonate. The DMEM provides optimized energy sources for protein production and
nucleic acid metabolism while limiting toxic ammonia build-up. It is to be used with 5%
CO2 to maintain pH. The DMEM contains phenol red to indicate the pH change in the
medium. Its color exhibits a gradual transition from yellow to red over the pH range 6.6
to 8.0. Phenol red will turn bright pink when the whole solution’s pH is > 8.1.
2) Fetal bovine serum (FBS) from HyCloneTM (Logan, UT): it is the major
supplement (10% v/v) of the cell culture medium as recommended from ATCC. It
contains mostly proteins but also growth factors, hormones, amino acids, sugars, trypsin
inhibitors, and lipids. The serum was defined for optimized performance and all the sera
are from the same lot to keep the consistency throughout the whole research period.
3) Penicillin-Streptomycin-Glutamine from GIBCOTM: it is the recommended
supplement (1% v/v) as antibiotics in the cell growth medium. Its function in the medium
is to lower the risk of contamination in the cell culture.
4) Dimethyl sulfoxide (DMSO): it is the recommended supplement (5% v/v) in
the complete culture medium to construct cryoprotectant medium. The function of

49

DMSO in the cryoprotectant medium is to prevent cell membrane rupture from avoiding
crystallization of liquid in cells when they are cryopreserved.
5) Trypsin/EDTA from GIBCOTM: it is the main reagent used to enzymatically
detach and re-suspend cells on the cell culture vessels for harvesting and sub-culturing.
Trypsin is a serine protease found in the digestive system, where it breaks down proteins.
It is involved in numerous bio-technological processes. Actually, Trypsin/EDTA is a
combined method for detaching cells while trypsin cuts the adhesion proteins in cell-cell
and cell-matrix interactions, and EDTA acts as a calcium chelator, ‘mops’ up the
remaining divalent cations for the better performance of trypsin. 0.25% Trypsin/EDTA is
used in this study as recommended.
6) Dulbecco's Phosphate Buffered Saline (PBS) from GIBCOTM: PBS is a buffer
solution commonly used in biochemistry. It is a salty solution containing sodium
chloride, sodium phosphate and potassium phosphate. In this study, the PBS contains no
calcium or magnesium. It is usually used to rinse the cell layer after the removal of
culture medium and before application of Trypsin/EDTA to minimize the effect of the
trypsin inhibitor in the old medium. It is also used to rinse the cell layer after removal of
culture medium when there are more than normal amount of dead cells floating in the
culture or for any other reasons that require a “medium free” cell layer.
7) Urea from AldrichTM: Urea is an organic compound of carbon, nitrogen,
oxygen and hydrogen, with the formula CON2H4 or (NH2)2CO. In this study, a 0.5M urea
solution will be used to lyse the astrocytes monolayer for aECM as a gentle lysis solution,
which can kill the cells themselves but leaving the extracellular component that
astrocytes secreted behind.
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8) Stericup 0.22μm filter units from Millipore (Billerica, MA): the vacuum
filtration system includes a filter unit together with a receiver flask which can later serve
as container for the filtered liquid. The 0.22μm pore size on the filter membrane is
suitable to remove bacteria and particle that may cause contaminations in the cell culture.
This system is used to filter the supplemented media and other solutions that need
sterilization in the experiments.
5.2.4 Other Equipments and Lab Wares
Major equipments are: bio-safety laminar flow hood, incubator, chemical flow
hood, centrifuge machines, lyophilizer, phase contrast microscope, fluorescent
microscope, scanning electric microscope, confocal microscope, TECAN micro plate
optical reader, TEER measurements chambers etc. These specific instruments will be
mentioned respectively where they are used.
Major labware are: electric pipettor, various pipettes, pipettor, matching pipet tips,
multi-channel pipettor, matching pipet tips, polypropylene conical centrifuge tubes,
forceps, Hemacytometer, etc.
5.3 Engineering Astrocytes Derived aECM
5.3.1 Theoretical Basis
It has been acknowledged that cells produce and interact with their extracellular
components in an organized matrix better known as ECM(96). In the central nervous
system, the ECM is located between astrocytes and cerebral capillaries(97). This ECM is
reported to provide structural support as well as signaling directions for brain
microvascular endothelial cells(97). There’s proof that bovine aortic endothelial cells
cultures on glial ECM showed dramatically higher activity of γ-GTP than those cultured
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on normal vessels(97). In the construction of the in vitro blood-brain barrier model, it
would be beneficial to observe the interaction between endothelial cells and the ECM
created by astrocytes which will probably lead to a more successful way of establishing
the particular model.
5.3.2 Methods
A layer of acellular extracellular matrix (aECM) will be prepared according to the
protocol by Mizuguchi et al. (97). In the beginning, rat astrocytes were seeded at the
density of 2×104 cells/well on a 12-well plate. The culture media (fully supplemented
DMEM) was changed daily in order to achieve the best proliferation, especially when the
cells were getting confluent. The cells were kept growing for a consecutive 10-day period
until full confluency was reached. On the last day, the media was removed and the
confluent cell layers were rinsed with cold PBS twice. Then the cells were incubated with
0.5M urea for 10 minutes to lyse the cells at room temperature. After the treatment, the
layer was decellularized and ready to be used as aECM in the in vitro model. The
resulting aECM was rinsed with PBS carefully 10 times to remove cell debris as well as
the urea residues. The aECM could be kept soaked in PBS and stored in the fridge for up
to two weeks.
According to ATCC, the confluent astrocyte cell layer was found to “come off the
culture surface in a sheet” and difficult to dissociate in previous studies(98). The
phenomenon was consistent with the observation in the experiment. At the end of the 10day culturing period, a layer of confluent astrocytes was formed. This cell layer was
resilient and could even endure normal the trypsinization procedure without breaking up.
This feature was fully utilized in this specific research to successfully produce the aECM.
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Figure 8 shows an example of the automatically delaminated confluent astrocyte layer.
Such a confluent layer was a homogeneous sheet full of astrocyte cell bodies providing
an ideal scaffolding substrate when decellularized for endothelial cells seeding.

Figure 8 Delaminated confluent astrocytes layer
5.3.3 Scanning Microscopy (SEM)
At the end of the 10-day culturing period, selected confluent astrocytes layer and
the decellularized aECM were prepared for SEM examination. Briefly, samples were
fixed with 10% glutaraldehyde (Sigma-Aldrich, St. Louis, MO) overnight; the fixed
samples were then serially dried by 10%, 30%, 50%, 75%, 90% and 100% ethanol
(Fisher Scientific, Pittsburgh, PA). After the last drying, the samples were treated with
hexamethyldisilazane (HMDS) (Sigma-Aldrich, St. Louis, MO) for 3 min. Then, these
samples were mounted onto conductive carbon tabs and freeze-dried in the lyophilizer
(Labconco FreeZone Plus Freeze Dry Systems, 6L. Kansas City, MO) overnight. Final
samples were examined by JEOL JSM-6335 scanning electron microscope(JOEL Ltd.,
Tokyo, Japan).
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Figure 9 SEM picture of confluent astrocyte layer and decellularized astrocytes
layer at the magnification of × 2000
Figure 9 compares the distinguished SEM images at x2000 magnification for
normal and the decellularized astrocytes layer, respectively. The normal astrocytes in (A)
on the left appeared to be rounder and the microvilli were visible. From a closer look as
in Figure 10, the morphology of the astrocytes at the magnification of × 2000was very
similar to the commercial image example demonstrated by “Dennis Kunkel Microscopy,
Inc.” as Figure 11 shows. The characteristic endfeet of the astrocytes were clearly visible.
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Figure 10 SEM image of astrocytes at the magnification of × 5000

Figure 11 Demonstration of astrocyte single cell in SEM, commercially available
from Dennis Kunkel Microscopy, Inc.
As clearly showed in (B) in Figure 9, after being decellularized by the lysis
solution, the aECM looked different from the normal confluent astrocytes sheet. More
hollow spaces were observed for the decellularized astrocyte sheet demonstrating the
washed away dead cell bodies. However, the hollow space would be ideal to serve as the
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structural support for the endothelial cells seeding. The remaining extracellular
components from the astrocytes would also provide the endothelial cells a better biomimetic of the basement membrane found in the real brain.
5.4 Culture Design
5.4.1 Sample Setups

Figure 12 Schematic demonstrations of selected sample setups in the study
As the author’s goal was to establish an in vitro co-culture BBB model with
astrocyte derived aECM utilizing commercially available cell, in a total of 12 trials,
various setups were attempted to compare and evaluate the efficiency in order to
determine the optimal design. Some of the different sample setups are shown in
schematics drawings as Figure 12 shows. How the different samples were built has been
briefly described in the drawings. How the co-culture models were engineered will be
introduced with details in the next section.
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Upon the arrival of the astrocytes and endothelial cells from ATCC, the cells were
cultured on T-75 flasks to proliferate, respectively. After 5 days of incubation, cells on
each flask were trypsinized by 0.05% Trypsin/EDTA into cells suspensions. The cell
suspensions were centrifuged at 1500 RPM for 3 minutes in room temperature. The
pellets were resuspended with the freezing media (culture media containing 5% DMSO)
and distributed into 1ml cryo-vials under aseptic environment. The cryo-vials were first
frozen at -80ºC for 24 hours and then transferred into liquid nitrogen cell preservative
tank for future use. 20 vials of each cell type were produced in the aforementioned
procedure, with roughly 200×104 cells/vial. All the subsequent experiments were carried
out using the cells from the vials and the passage numbers were all within 10.
5.4.2 Engineering the Co-Culture Samples

Figure 13 Schematic drawing of steps in building “CO” and “CO+aECM” samples
Figure 13 shows how the co-culture models were built on the COL inserts. In the
beginning of culture period, the inserts were inverted with basal sides facing upwards and
placed in a deep glass dish. Astrocytes were seeded onto the basal sides at the
concentration of 5,000 astrocytes/insert. Culture media was carefully added into the deep
dish in order not to wash away the just seeded cells. The deep dish was kept untouched in
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the laminar flow hood for 30 -60 minutes before being carefully transferred into the
incubator. Figure 14 demonstrated how the inverted seeding looked like in real life. The
astrocytes were incubated at 37°C in an atmosphere with 5% CO2 for 3 days. Figure
16shows how the inverted inserts were incubated. In order to eliminate contamination, a
piece of Kimwipe® (Fisher Scientific) was loosely covered on the deep dish and secured
by a round glass plate. The glass plate had a unique shape that allowed air exchange for
the cells in the deep dish.
After three days of incubation, the astrocytes were assumed to attach to the basal
sides of the inserts and the inserts were inverted to their original orientation and placed
into the 24-well plates. For the CO setup, 5,000 endothelial cells were seeded onto each
inserts’ apical sides. For the CO+aECM setup, a piece of aECM produced as previously
described, was placed into each insert cup and then 5,000 endothelial cells were seeded
on top of the aECM. Following manufacture’s protocol, the media volume for the upper
chambers (insert apical sides) and lower chambers (insert basal sides) were 100µl and
600µl, respectively. All the plates were incubated at 37°C in an atmosphere with 5%
CO2. Figure 15 demonstrates the sample setups in the well plates.
For every trial, several different setups were attempted with at least 4 replications
for each different setup. For those cells that did not require astrocytes seeding on the
basal sides of the inserts, cells would be seeded on the apical sides of the inserts the same
time when endothelial cells for the co-culture samples were seeded at the seeding density
of 5,000 cells/insert.
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Figure 14 Astrocytes seeded on inverted inserts in the deep dish. A: side view; B: top
view
For the “Pseudo” setup where astrocytes grew on the bottoms of the wells while
endothelial cells grew on the apical sides of the inserts, the astrocytes were seeded at the
seeding density of 10,000 cells/well 3 days prior to the endothelial cells seeding.
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Figure 15 Sample plates. A: demonstration of how the inserts situated in the well
plates. B: one batch of samples
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Figure 16 Astrocytes seeded on the inverted inserts in the incubator
5.5 Astrocytes and Endothelial Cells Morphologies
Both astrocytes and endothelial cells started to attach and spread in the cell
culture vessel bottom within 12 hours of plating. Both cells were observed to attach and
proliferate well under routine maintenance. As described in previous chapters, astrocytes
and endothelial cells have distinct morphologies. 2 days after the cells were seeded;
pictures from an optical microscope of both cells in culture were taken by a camera.
Figure 17 shows the morphologies of astrocytes and ECs growing on tissue culture well
plates and COL Transwell inserts, respectively. All the pictures shown in this figure were
taken using a digital single lens reflex camera (Pentax K100D at 35mm focal length with
aperture of 1:4) directly from the eye-piece of an inverted microscope.
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200×

200×

200×

Figure 17 Cell morphologies observed from optical microscope under magnification
of ×200
Astrocytes’ star like shape is obvious from Figure 2(A). The author also noticed
the astrocytes grew faster than the endothelial cells and were more easily to aggregate.
Figure 2(B) shows endothelial cells spreading on the plastic well bottom. The typical
endothelial squamous shapes are also easy to distinguish from the picture. Endothelial
cells attached well on the collagen coated filter surface of COL Transwell inserts. The
structure of the collagen coated fibrous PTFE insert membrane could be identified under
the microscope in Figure 2(C). There was no obvious morphological difference between
the ECs growing on normal culture vessel and ECs growing on the COL Transwell
inserts.
5.6 Summary
The chapter focuses on the engineering of the in vitro co-culture samples. After
reviewing several currently available approaches attempted by other researchers, the
author went to with the explaining of her own design of the sample setups. Different
sample setups were introduced and compared by both schematic drawings and real life
photographs. As part of the novel approach in this dissertation, the theoretical basis of
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aECM and how it was produced was revealed in this chapter. SEM images compared the
difference between a normal confluent astrocytes layer and the aECM. The morphologies
of the chosen cell lines were looked at in the end of the chapter too.
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CHAPTER VI TEER MEASUREMENTS
6.1 Introduction
As a convenient and reliable, yet non-destructive method, trans-endothelial
electric resistance (TEER) measurements have been employed by various researchers to
evaluate and monitor the growth of in vitro endothelial cell cultures, which in this
particular case, is to evaluate the in vitro endothelial tight junctions.
The EVOM endothelial voltohmmeter from World Precision Instruments, Inc.
(WPI, Sarasota, FL) was the first instrument designed specially to make routine TEER
measurements in cell culture research. As a standard accessory, the EVOM comes with a
set of STX2 electrodes (“chopsticks”) to directly measure TEER values from the inserts
in the well plates. The two electrodes are of different lengths. When they are dipped into
the cell culture well, the shorter electrode goes into the insert upper chamber while the
longer one stays outside of the insert in the lower chamber of the well. During the TEER
measurements, the electrodes should not touch the bottom of either the insert or the well.
Figure 18 shows the EVOM and STX2 electrodes in real life.

Figure 18 TEER measurement instrument. A: EVOM Endothelial Voltohmmeter.
B: STX2 electrodes measuring TEER value of the insert in the well plate
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Figure 19 Endohm TEER measurement chamber for 6.5mm diameter Transwell
inserts
Endohm tissue resistance measurement chamber is another type of TEER
measurement tool designed to be used together with EVOM for various insert types and
more accurate quantitative measurements. Figure 19 is a demonstration of an Endohm
chamber designed for 6.5mm diameter Transwell inserts which suit the 24-well plates.
This Endohm chamber has the exact size of the well from the 24-well plates. The
chamber and its cap each contain a pair of concentric electrodes, respectively. When
taking TEER measurements, the Endohm should be filled with media whose volume is
equal to that from the normal cell culture condition. The media should be the same
culture media but without serum in order to avoid the proteins from the serum to
aggregate on the electrodes and affect the measurement accuracy. The height of the cap
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electrode can stay fixed for a chosen insert which eliminates the inconsistency between
measurements.

What’s

more,

Endohm’s

apposing

circular

electrodes

which

symmetrically situated beneath and above the membrane allow a more uniform current
density to flow across the membrane than with STX2 electrodes. According to WPI, the
background noise from the resistance of a blank insert is reduced from 150Ω (as with the
STX2 electrode) to less than 5Ω for Endohm chambers.
6.2 Methods
In the earlier trials of the experiment, the STX2 electrodes were employed in the
TEER measurement because it came with the EVOM device. However, the “chopsticks”
showed unpredictable inconsistency in the readings, which were easily affected by the
vertical position of the electrodes or the media levels in the cell culture chambers. Thus
after the initial 3 trials, Endohm was purchased to do the rest of the TEER measurements.
For all the samples setups, the number of days were counted starting from the
endothelial cells were counted. For examples, for the “CO” and “CO+aECM” samples,
the day when the endothelial cells were seeded on the apical sides of the inserts was
defined as Day-0. The endothelial cells were untouched on Day-1 so that they could
recover from cryo-preservation or sub-culturing dislodging shock. Starting from Day-2,
the TEER values were measured daily for the membranes on the inserts using Endohm
chambers connected with EVOM. Since cells on the apical sides of the inserts from other
samples setups such as “EC” and “Pseudo” were seeded on the same day when the
endothelial cells for the CO and CO+aECM samples were seeded, the TEER
measurements could thus be synchronized.
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Starting from Day-2, TEER measurements were taken for all the sample insert
membranes. First of all, the culture media was removed from both upper and lower
chambers of the samples. The upper and lower chamber of the sample wells containing
inserts were filled with 100µl and 600µl warm serum-free DMEM (Gibco), respectively.
600µl of the warm serum-free DMEM was added to the Endohm chamber too. Then the
each insert was picked up carefully by a pair of sterile tweezers and placed into the
Endohm chamber to be measured by the EVOM. After the measurements, the inserts
were placed back into their corresponding wells. The serum-free DMEM was replaced by
normal culture media again and the samples were put back into the incubator.
During the measurement, two readings were taken for each insert and the original
results were expressed as the average values of the readings. The author found the
differences between the two readings were usually ±1. In the initial several trials, the
TEER for a blank insert was always measured alongside the samples. As the Endohm
manufactory stated, the TEER reading for the blank insert was always around 5
throughout the experiments. Starting from Trial #4, the adjusted TEER measurement
results were recorded as the actual readings minus 5. The final results were all adjusted
based on the aforementioned conditions and expressed in Ω cm2, which were calculated
by multiplying the adjusted readings by the effective surface area (0.33 cm2 for Transwell
inserts for 24-well plates) of the filter membrane.
6.3 Results and Discussions
A total of 13 trials were performed in the dissertation work. Non-collagen coated
inserts were employed in the study from Trial #1 through Trial #7. The COL inserts were
used starting from Trial #2. The results for both types of inserts were presented in the

67

dissertation annual report. However, both the committee members and the author were
convinced that due to the poor cell attachment of the non-collagen coated inserts, these
inserts were not suitable for the specific in vitro study and the corresponding results
should not be included in the final dissertation discussion. For this reason, only the TEER
values from COL samples of are presented in the following graphs starting from Trial #2.
The values were expressed in average ± standard deviation (4 replications per each trial).
As shown from the graphs, in the initial stage of the dissertation the cell cultures
were maintained for 8 or 9 days depending on the lab schedules and available resources.
Because of unexpected contaminations, Trial #4 was terminated before any analysis or
data acquisition.
TEER vs. time for COL Transwell Plate -- Trial #2
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Figure 20 TEER measurement results for Trial #2
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TEER vs. time for COL Transwell Plate -- Trial #3
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Figure 21 TEER measurement results for Trial #3

TEER vs. time for COL Transwell Plate -- Trial #5
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Figure 22 TEER measurement results for Trial #5
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TEER vs. time for COL Transwell Plate -- Trial #6
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Figure 23 TEER measurement results for Trial #6
TEER vs. time for COL Transwell Plate -- Trial #7
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Figure 24 TEER measurement results for Trial #7
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TEER vs. time for COL Transwell Plate -- Trial #8

350.0
300.0

TEER (Ω cm^2)

250.0
EC

200.0

CO
150.0

CO + aECM

100.0
50.0
0.0
2

3

4

5

6

7

8

9

Days

Figure 25 TEER measurement results for Trial #8
TEER vs. time for COL Transwell Plate -- Trial #9
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Figure 26 TEER measurement results for Trial #9
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TEER vs. time for COL Transwell Plate -- Trial #10
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Figure 27 TEER measurement results for Trial #10
TEER vs. time for COL Transwell Plate -- Trial #11
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Figure 28 TEER measurement results for Trial #11
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TEER vs. time for COL Transwell Plate -- Trial #12
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Figure 29 TEER measurement results for Trial #12
TEER vs. time for COL Transwell Plate -- Trial #13
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Figure 30 TEER measurement results for Trial #13
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The trend of the results from the earlier trials (Trial #2 through Trial #6) showed
that the TEER values for “CO” samples started at around or just below 250 Ω cm2 and
gradually raised with the highest being 286.6 ± 3.0 Ω cm2 in Trial #5 on Day-7. The
TEER values for the “CO” samples were testified to be statistically significant higher
than those of the other samples by one-way ANOVA analysis (α = 0.05). The TEER
values were lower than the primary BBEC culture by Garberg et al. which were 500-800
Ω cm2 (7), but significantly higher than the ECV304 cell line (100 Ω cm2), which has
been used for feasible immortalized BBB models by several groups, and found to have
relative high correlation between in vivo and in vitro permeability studies(44, 87, 88). As
in vitro models, the TEER values were not expected to be as high as those found in in
vivo environment, or even as high as the aforementioned primary cell cultures. The
results from these earlier trials fall between the range of established primary culture and
relatively successful immortalized BBB models, the author felt the study could continue
based on the current sample setups with necessary improvement of experiment
techniques. The repeatability should be an important aspect to evaluate in the assessment.
In the earlier trials, the author was still trying to figure out the optimal method to
produce the aECMs, especially in the lysis procedure. While at the same time “Pseudo”
setups were attempted by the authors following examples by other researchers. However,
the author found out that the TEER values were not significantly different between
“Pseudo” and “EC” samples by student t-test analysis (α = 0.05) in a day-to-day
comparison throughout the initial 3 trials. In the “Pseudo” case even though astrocytes
presented remotely in the same chamber, but their secretions may not reach the high
enough concentration so as to affect the junctional formation between the endothelial
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cells. Given limited funding and materials, the author decided not to continue with the
“Pseudo” setup. The TEER values for “AS” and “EC” samples were not significantly
different either. Since this research was to examine electrical resistance between
endothelial cells, the TEER values of the astrocytes layers were no longer displayed in
the following trials.
By the beginning of Trial #7, the author had mastered the effective method to
produce aECMs with consistent quality so the aECMs were included in the co-culture
sample building starting from Trial #7. Trials #7 through #10 demonstrated the TEER
values for both “CO” and “CO+aECM” samples were significantly higher than the “EC”
samples. The “CO+aECM” samples showed significantly higher TEER values than the
“CO” samples. Statistical study were carried out by one-way ANOVA analysis (α =
0.05). However, since there were no literature “CO+aECM” TEER value data to compare
with the “CO+aECM” data. Additional studies including transport study and immunochemistry studies needed to further evaluate the endothelial tight junction in all the
samples.
Similar as the earlier trials, the TEER values for the “EC” samples in Trials #7
through #10 were maintained at a relatively stable level while the values slightly
increased over the culture period. The TEER values for the “CO” and “CO+aECM”
samples were more established starting from Day-4 which continued to increase until
Day-7. However, the TEER values for these co-culture models were seen to slowly
decrease from Day-8 for the majority of the samples. Thus Day-7 was selected as the
optimal day for transport studies which will be introduced in the next chapter. Trials #11
through #13 were dedicated in solute transport study and their culture period were
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terminated on Day-7. In these later trials, the “CO+aECM” samples still showed higher
TEER values and those of the “CO” samples and both co-culture samples’ TEER values
were significantly higher than the “EC” samples.
For all the trials, the TEER values for the co-culture samples were consistent.
One-way ANOVA analysis showed that “EC”, “CO” and “CO+aECM” samples were
significantly different from each other on a daily basis: the TEER values for both “CO”
and “CO+aECM” samples were significantly higher than the “EC” samples for all the
trials by one-way ANOVA analysis when α = 0.05 (p = 2.06×10 -12 on Day-7). The TEER
values for “CO+aECM” samples were also significantly higher than the “CO” samples by
one-way ANOVA analysis when α = 0.05 (p = 3.78×10

-5

on Day-7). The p-value for the

significance between “CO” and “EC” samples was 3.31×10-8 on Day-7.
6.4 Summary
This chapter examined the endothelial tight junction formation by evaluating the
sample membranes’ electrical resistance through a method call TEER measurement.
“EC”, “Pseudo”, “CO” and “CO+aECM” were among the test candidate. “AS” samples’
TEER values were also taken in the earlier trials, and they showed similar readings as
those of the “EC” and “Pseudo” samples.
The TEER values for “EC” “CO” and “CO+aECM” samples were found to be
consistent between different trails. “CO” and “CO+aECM” samples’ TEER values were
both significantly higher than those of the “EC” samples, and at the same time
“CO+aECM” samples demonstrated significantly higher TEER values than the “CO”
samples. The values for both of the co-culture samples were comparable to some
currently available in vitro BBB model attempts and these samples were approved to be
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relevant setups for BBB in vitro modeling. The TEER values for these samples gradually
establish through Day-7 and started to decrease from Day-8. “EC”

“CO” and

“CO+aECM” samples from Trials #11 through #13 were engaged in solute transport
study in the next chapter.
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CHAPTER VII TRANSPORT STUDIES
7.1 Introduction
As was introduced in previous chapters, the BBB keeps out almost all nonlipophilic molecules larger than 500 Dalton from entering the brain blood stream freely
through passive diffusion. In this chapter, several different compounds were proposed to
test the permeability of the in vitro samples over the time.
Table 4 Proposed test compounds in the BBB transport studies
Molecular

UV-Vis

Weight

Absorbance Peak

Calcein

622.55

490nm

Caffeine

80.70

273nm & 232nm

579.98

245nm

Compound Name

Doxorubicin
(DOX)
Keppra

Sucrose
Nicotine

Vincristine sulfate

Hydrophilic
Hydrophilic;
Soluble in chloroform
Hydrophobic
Hydrophilic;

®

(levetiracetam)

Solubility

170.21

244nm

Soluble in: chloroform,
ethanol & acetonitrile

342.30
162.23

923.04

240nm
259nm

Hydrophilic
Hygroscopic, miscible with
water in its base form
Water solubility:

N/A

≥ 10 mg/ml at 75° F
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A list of test compounds was proposed in the beginning of the dissertation work
and is listed in Table 4. The different compounds were selected based on their different
sizes, solubility and functionalities. For example, sucrose has been a popular candidate
among researchers in evaluating BBB permeability. DOX and Keppra® were selected to
be the drug candidates. DOX is a chemotherapy agent and has been reported as a known
substrate of p-glycoprotein which actively repels this drug out of the brain. Keppra® is an
anti-epilepsy agent which is claimed to be able to pass the BBB by its manufactory (UCB
Pharmaceuticals, Inc.). Vincristine, another chemotherapy agent with the molecular
weight of more than 900 Dalton was also selected as a drug candidate in the experiment.
Caffeine and nicotine was selected because their small molecular size and their
possibility to pass through the BBB. Calcein is a molecule that has not been reported to
affect the brain, and its molecular size is around the BBB molecular weight threshold and
it would be interesting to see how the in vitro samples would react to it.
Because of the on campus facility restraints, the author was not able to conduct
radio labeled transport study which is the most popular approach in this field. Instead, an
optical spectrophotometer was employed in determining the amount of solute in the
experiments. Spectrum scans at the wavelength of 200nm – 800nm were preformed on all
the proposed compounds to determine their absorbance peak, respectively. The
absorbance listed in the above table all came from such experiments.
7.2 Methods
In vitro samples from several later trials were selected for the transport studies. As
indicated in the previous chapter, the TEER values reached their peaks on Day-7 and
started to slowly lessen over the next couple of days. Hence Day-7 was decided as the
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day for the transport studies for optimal results. Trials #11 through #13 were dedicated
for the transport studies. Since each setup had four replications in each trial, one or two of
the replications would be dedicated for one type of test compound in the transport study.
One blank insert for each different compound would be used as the control to undergo
same test procedures. The test compounds were pre-dissolved in Phenol red-free DMEM
(Invitrogen, Carlsbad, CA). The stock concentration of the test compound solutions were
empirically decided to be 50µg/ml, which was the optimal concentration for the working
range of the Cary 100 UV-Vis spectrophotometer (Varian, Palo Alto, CA). Silica
spectrophotometer cuvettes and cuvette washer/drier (Sigma-Aldrich) was employed in
the experiments for more accurate and consistent readings. Figure 31 shows the
spectrophotometer and cuvette images from their manufactories, respectively.

Figure 31 Measurement instruments in the transport studies. A: Cary 100 UV-Vis
spectrophotometer. B: Silica spectrophotometer cuvette
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At the end of the 7-day culturing period, growth media were removed from
selected samples following by gentle rinsing with warm phenol red free pure DMEM.
Then 200μl of the stock concentration of compound solutions were added to the upper
chambers of each insert. The lower chambers of each insert were supplemented with
1220μl of phenol-red free pure DMEM, respectively. The media levels inside and outside
of the insert were thus kept leveled to avoid any hydraulic force influence. The sample
plate was incubated at normal conditions with 5% CO2 and at 37ºC except during sample
extraction. At predetermined times (15, 30, 45, 60, 90 and 120min); 110μl of sample was
withdrawn from the lower chamber of each sample, respectively. 21μl of compensation
volume of the solution was removed from the upper chamber of the corresponding
sample to maintain the media volume balance between two chambers. The110μl
extracted samples were kept in sterile capped 1ml centrifuge vials (Fisher Scientific) for
later measurement. Because of the small amount of the sample size, the measurement
should be taken immediately following the sample extraction to keep the error from
sample evaporation to the lowest level.
Optical absorbance of each sample was determined by UV absorbance at their
unique peaks using the Cary-100 spectrophotometer. In the initial several trials, the
readings were taken twice for each sample in order to see if there was any variance in the
readings. It was found out that for the same sample, when scanned under the same
condition in adjacent times, the reading were always uniform. However the silica cuvette
needed to be washed every time before new measurement and there was only one pair of
such cuvette. Considering the small amount of the sample, it would be unrealistic to store
the sample for future use. Thus one reading was taken for each sample in majority of the
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experiment and the sample was dumped right after the measurement to save time for the
rest of the measurements.
Table 5 Serial dilution concentration demonstration.
Dilution # Concentration (µg/ml)
0

50.0

1

37.5

2

28.1

3

21.1

4

15.8

5

11.9

6

8.90

7

6.67

8

5.00

9

3.75

10

2.82

11

2.11
Serial dilution calibration curves were made for each candidate compound in

order to later determine the concentration of the sample solutions. For each test
compound solution, starting from the stock concentration of 50µg/ml, a 75% gradient
was made for each subsequent dilution for a total of 12 serially diluted samples. A
demonstration of the concentration of serially diluted samples is displayed in Table 5.
The optical absorbance of the diluted samples were read by the spectrophotometer at their
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unique peaks and plotted against the corresponding concentration. A linear curve was
fitted to each plot to obtain the relationship between the absorbance and the
concentration. For compounds that had saturated readings on the higher concentrations,
the saturated values were discarded but a total of more than 10 readings should be taken
for each compound. For compounds that had more than one absorbance peaks in the UVVis range, all the possible curves were drawn and the one with the highest R2 value was
selected to be used as the absorbance – concentration calibration curve. Demonstrations
of the spectrum scans and the calibration curves are displayed in Figure 32 through
Figure 36. Figure 32 shows an example of calcein concentration serial dilution scans
from Trial #9 at the absorbance peak of 490nm, where the starting concentration was
28.125µg/ml, and the dilution gradient was 75%. Figure 33 shows the calcein
concentration serial dilution absorbance vs. concentration chart from Trial #9 at the
absorbance peak of 490nm. The starting concentration was 28.125µg/ml, and the dilution
gradient was 75%. R2 = 99.30%. Figure 34 shows the example of caffeine concentration
serial dilution absorbance vs. concentration chart from Trial #11. The starting
concentration was 28.125 µg/ml, and the dilution gradient was 75%. Absorbance peak1
was at 273nm, where R2 = 99.99%. Absorbance peak2 was at 232nm, where R2 =
97.80%. Figure 35 shows an example of DOX concentration serial dilution absorbance
vs. concentration chart from Trial #11. The starting concentration was 50 µg/ml, and the
dilution gradient was 75%. Absorbance peak1 was at 502nm, where R2 = 98.37%.
Absorbance peak2 was at 232nm, where R2 = 99.79%. Figure 36 shows an example of
sucrose concentration serial dilution absorbance vs. concentration chart from Trial #9.
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The starting concentration was 50 µg/ml, and the dilution gradient was 75%. Absorbance
peak1was at 292nm, and absorbance peak2 was at 240nm.

Figure 32 Example of calcein concentration serial dilution scans

Absorbance

Absorbance vs. Concentration -- Calcein (Trial #9)
3.50
3.00
2.50
2.00
1.50
1.00
0.50
0.00
0.00

y = 0.1006x + 0.0769
R2 = 0.993

5.00

10.00

15.00

20.00

25.00

30.00

Concentration (µg/ml)
Absorbance peak (490nm)

Figure 33 Example of calcein concentration serial dilution Absorbance vs.
Concentration chart

84

Absorbance

Absorbance vs. Concentration -- Caffeine (Trial #11)
1.40
1.20
1.00
0.80
0.60
0.40
0.20
0.00
0.00

y = 0.0473x - 0.0544
R2 = 0.9999

y = 0.0227x - 0.1252
R2 = 0.978
5.00

10.00

15.00

20.00

25.00

30.00

Concentration (µg/ml)
Aborbance peak1(273nm)

Absorbance peak2(232nm)

Figure 34 Example of caffeine concentration serial dilution Absorbance vs.
Concentration chart
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Absorbance vs. Concentration -- DOX (Trial #11)
1.40
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1.00
0.80
0.60
0.40
0.20
0.00
0.00

y = 0.0295x - 0.1037
R2 = 0.9979
y = 0.0095x - 0.0483
R2 = 0.9837
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40.00
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concentration (µg/ml)
Absorbance peak1 (502nm)

Absorbance peak2 (231nm)

Figure 35 Example of DOX concentration serial dilution Absorbance vs.
Concentration chart
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Absorbance vs. Concentration -- Sucrose (Trial #9)

Absorbance

0.50
0.40

R2 = 0.2934

0.30
0.20
0.10
0.00
0.00

R2 = 0.0101
10.00

20.00

30.00

40.00

50.00

Concentration (µg/ml)
Absorbance peak1 (292nm)

Absorbance peak2 (240nm)

Figure 36 Example of sucrose concentration serial dilution Absorbance vs.
Concentration chart
The serial dilution curves indicated that several compounds were not suitable to
be used as test candidates in the particular experiment. Sucrose and Vincristine simply
did not show meaningful in optical absorbance readings between different concentrations.
An example of such case is shown in Figure 36 for sucrose solution. Nicotine was an oily
liquid, and was very difficult to clean from the quartz cuvette. Since the same cuvette
would have to be reused throughout the experiment to eliminate the error between
different cuvettes, washing became a very important procedure in the experiment. The
author found once contacted nicotine, it would take more than 10 minutes to clean the
cuvette with multiple rinses and solvent. Considering the large amount of samples
waiting to be read and the tiny amount of the sample sizes, the samples could dry out
while waiting. So nicotine was finally excluded from the candidate test compound list in
order to save time and most importantly, to eliminate potential error caused by the
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changing of the sample solution volumes. Finally, calcein, caffeine and DOX were
chosen to participate in the solute transport studies.
The solute concentrations of the extracted samples were calculated based on the
corresponding calibration curves obtained in each trial. Mass was calculated based on the
solute concentration. Effective permeability coefficients were calculated subsequently
using following equation.

M

M 
V 
P = 

A
t



R

D

e

V is the volume of the donor solution in the upper chamber, A is the surface area of the
insert membrane, MR is the mass of the test compound in the lower chamber (mol), MD is
the mass of the donor compound in the upper chamber (mol), and t is the time (sec). Even
though compensation volume of liquid was removed each time from both chambers to
maintain the liquid level, the mass was calculated based on the initial volume because
concentration was the value to be recorded, which would not be affected by the changing
of the volume. No group has reported solute transport for the selected test compounds in
similar setups, and the mass transport profiles are more of the investigation focus.
7.3 Results and Discussions
7.3.1 Transport of Calcein
Calcein (MW = 622.55) had UV absorption peak at around 490nm and was used
as a reference indicator in the experiments to evaluate the compound transport across
different sample membranes . Calcein permeability profile is shown in Figure 37. All the
samples with cells prevented more calcein transport over time across the membrane
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comparing to the blank insert membranes. Both of the co-cultured samples demonstrated
greater ability to prevent calcein from permeating across the membranes over the time
compared with ECs only sample. The “CO+aECM” samples prevented most amount of
calcein from diffusing across the sample membrane. One-way ANOVA analysis showed
that all the three samples setups were significantly different from each other over time
(when α = 0.05, P15min = 1.66×10-6, P30min = 2.42×10-9, P45min = 1.71×10-9, P60min =
3.67×10-9, P90min = 1.01×10-8, P120min = 2.25×10-8). All the samples were significantly
different from the blank control over time (when α = 0.05, P15min = 4.58×10-10, P30min =
2.66×10-5, P45min = 1.65×10-5, P60min = 1.08×10-5, P90min = 4.78×10-6, P120min = 3.34×10-6).
Calcein is considered “inert” regarding to the BBB, the transport profile demonstrated in
this particular study is a proof of the passive transport of calcein across the BBB, where
the solute transport is related to the impedance from the sample membranes, which were
had a lot to do with the thickness of the samples.
7.3.2 Transport of Caffeine
Caffeine (MW=80.7, UV absorbance peak at around 275nm) is a small molecule
and is known to be distributed from plasma into the brain and central nervous system(99,
100). Caffeine permeability profile from Trial #11, 12 and 13 is collectively shown in
Figure 38. No significant difference between the “EC” samples and the blank controls
(when α = 0.05, P15min = 0.0499, P30min = 0.1612, P45min = 0.1118, P60min = 0.0649, P90min =
0.7130, P120min = 0.0918). No significant difference between the “CO” & “CO+aECM”
samples (when α = 0.05, P15min = 0.6927, P30min = 0.5030, P45min = 0.3997, P60min =
0.7548, P90min = 0.6773, P120min = 0.6849).

Co-culture samples were significantly

different from the “EC” samples (when α = 0.05, P15min = 0.0009, P30min = 0.0001, P45min
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= 0.0019, P60min = 0.0049, P90min = 0.0032, P120min = 0.0254). Caffeine is reported to be
actively transported across the BBB, and the data in this study demonstrated this fact,
where the transport profiles between all four samples were close. Even though there were
significant differences between groups, the p value was not as small as compare to the
numbers in the calcein study. And the different between “CO” and “CO+aECM” samples
were really negligible.
7.3.3 Transport of DOX
Doxorubicin (DOX, MW=579.98) is a chemotherapy agent and a known substrate
of p-glycoprotein on the BBB (101). In the experiment, DOX was used as one of the drug
candidates to test the transport across the in vitro model sample membranes. Calcein
permeability profile from Trial #11, 12 and 13 is collectively shown in Figure 39. Oneway ANOVA analysis revealed that all the three samples setups were significantly
different from each other (when α = 0.05, P15min = 1.72×10-6, P30min = 1.69×10-6, P45min =
2.31×10-6, P60min = 4.27×10-6, P90min = 1.08×10-5, P120min = 0.0001). All of the samples
were also significantly different from the blank control (when α = 0.05, P15min = 8.04×108

, P30min = 6.05×10-8, P45min = 5.16×10-8, P60min = 5.92×10-8, P90min = 7.48×10-8, P120min =

9.25×10-8). Four out of the six of the “”CO+aECM” samples prevented significantly
more DOX from permeating through the membrane than the “CO” samples (when α =
0.05, P15min = 0.0245, P30min = 0.0616, P45min = 0.0444, P60min = 0.0422, P90min = 0.0456,
P120min = 0.0657).
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Figure 37 Calcein mass transport profiles.
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Figure 39 DOX mass transport profiles.
Since no group has reported solute transport for the selected test compounds in
similar setups, the comparison of the mass transport profiles between different sample
setups is more of the investigation focus. Since calcein hasn’t found to be reactive with
the BBB, and its molecular weight is around the threshold, it was employed in the
transport assessment because of its excellent optical absorbance calibration curves. The
amounts of calcein transported across the samples membranes were used as an indicator
for molecules of its size. Statistical analysis showed that all the sample setup was
different between each other, and the “CO+aECM” samples prevented the most amount
of calcein transport with the effective permeability coefficient equaled to (1.33 ± 0.25)
×10-6 cm sec -1. As a small molecule with its molecular weight well below the threshold,
the amounts of caffeine transported across the membranes were much more than those of
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calcein. However, there was no significant difference found between the “EC” samples
and the “Blank” samples. or between the “CO” samples and the “CO+aECM” samples.
Even though caffeine solute transport through the “CO” or “CO+aECM” samples was
statistically significantly lower than that of the “EC” or “Blank” samples, the p-values
were not as low as those in comparison in the calcein transport profiles. The effective
permeability coefficients for caffeine in the different setups were almost four times of
those of calcein’s. These results were not surprising because caffeine was reported to be
actively transported across BBB by saturable mediated processes and the results verified
the theory by the high efficient permeability coefficient [30, 31]. The assessment here
served as an example of the caffeine solute transport across the BBB. For the DOX
transport profiles, the transport profiles of both the “CO” and the “CO+aECM” samples
were statistically significantly lower than that of the “EC” samples. And the majority of
the “CO+aECM” samples prevented significantly more DOX from being transported
across the sample membranes than those of the “CO” samples. The next step for the
authors would be to evaluate the existence of p-glycoproteins on the sample membranes,
but for now the available results could be concluded as a phenomenal proof of the
existence of some DOX-resistant component on the co-culture sample membranes, which
were found to be more on the “CO+aECM” samples than those on the “CO” samples.
7.3.4 Permeability
The effective permeability coefficients of different test compounds across
different sample setups are summarized in Table 6. The values are expressed in average ±
standard deviation for trails # 11, 12, and 13. The permeability coefficients were
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comparable to those found in Garbergs et al.’s various BBB in vitro model attempts, thus
proving that the samples had the potential to serve as relevant BBB in vitro model. The
only comparable value from literature is the caffeine in vivo “mouse brain uptake assay”
where the apparent permeability coefficient is (8.1 ± 1.2) ×10-6 cm/s, which is close to the
values from the “CO” samples.
Table 6 Permeability of different test compounds across different sample setups
Pe (×10-6 cm sec -1)

Calcein

Caffeine

DOX

“EC” samples

2.90 ± 0.55

11.07 ± 3.02

4.87 ± 1.18

“CO” samples

2.05 ± 0.48

8.33 ±1.45

2.66 ± 0.80

“CO+aECM” samples

1.33 ± 0.25

8.14 ± 1.61

2.38 ± 0.73

Blank controls

7.10 ± 0.35

14.44 ± 0.68

8.61 ± 0.46

The transport profiles and permeability coefficient values look better than the
results from the TEER measurement in terms of closeness to the in vivo values. However,
this does not mean there is inconsistency between these two sets of measurements. In
fact, after the transport sampling procedures for calcein, a noticeable amount of calcein
could be found to be retained by the sample membranes by showing of the fluorescent
yellow color. This could result in lower reading of actual amount of transported solute,
and thus the less detectable solute in the transport studies.
7.4 Summary
This chapter looked at solute mass transport through diffusion for calcein,
caffeine and DOX. The membranes allow the small molecule caffeine, which was also
actively transported by the BBB to pass through, while prevented in proportion of calcein
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and DOX. However, the membranes reacted differently between calcein and DOX. The
mass transport for calcein solutions followed more of a time and concentration dependent
route. While the co-cultures were able to prevent significant amount of DOX from
passing through the membrane while “EC” samples permitted much more DOX to go
through. The comparable effective permeability coefficients of the co-culture samples
demonstrated they may serve as potential relevant BBB in vitro models.
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CHAPTER VIII TIGHT JUNCTION PROTEIN EXPRESSION
8.1 Western Blot Analysis
As introduced in previous chapters, there are several specific proteins exist on the
BBB endothelial tight junctions. Occludin is one of the earliest identified tight junction
protein. The author employed western blot analysis to examine the expression of occludin
on different samples in the experiments. The selected samples included EC, CO and
CO+aECM samples. Detailed procedures and results are described in the following
sections.
8.1.1 Introduction to Western Blot Techniques
Western blot is a technique to detect a specific protein from a given mixture of
proteins from tissue extract or lysate. It is a technique composed of gel electrophoresis
and immunochemical detection. This technique is very useful to identify a protein from a
complex mixture of proteins that are not radio labeled.
Sodium dodecyl sulfate polyacrylamide (SDS-PAGE) gel electrophoresis is the
most popular technique used by the scientists to electrophoretically separate denatured
proteins according to their molecular weight. The sieving property of the SDS-PAGE gel
electrophoresis is based on the absolute concentrations of acrylamide and bisacrylamide,
which determine the size of the pores on the gel. SDS is a highly negatively charged
detergent employed to proportionally bind to the protein according to their molecular
weight. Thus during the gel electrophoresis, the SDS-bound protein complexes migrate
toward the anode side, during which the larger the protein size, the slower it moves. So at
the end of the gel electrophoresis, proteins are separated and distributed on different
locations of the gel.
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After the proteins are electrophoretically separated, they are transferred onto a
piece of nitrocellulose membrane in the next step. Primary antibody will be applied to the
membrane to detect the target protein. The primary antibody is usually raised in a
different host species against the target protein. It can also be obtained from immune cell
culture which is exposed to the target protein.
In order to prevent interactions between the membrane and the primary antibody
for the detection of the target protein, 5% bovine serum albumen (BSA) or non-fat dry
milk are employed to soak the membrane before the application of the primary antibody.
The blocking procedure makes sure the areas on the membrane which are not attached by
the target protein are attached by the inert BSA or the milk proteins. Thus when the
primary antibody is applied, it will only bind to the target protein and the background
noise is significantly reduced.
In the next step, secondary antibody is employed to detect the primary antibody
for a species-specific portion on it, e.g. anti-mouse secondary antibody will detect mousesourced primary antibody. The secondary antibodies are usually associated with a
reporter enzyme such as, most commonly, horseradish peroxidase (HRP) for further
detection. The HRP on the secondary antibody can cleave a chemiluminescent agent such
as lunimol, which is able to exhibit chemiluminescence in proportion to the amount of the
protein. Thus in a dark room, the generated chemiluminescence from the nitrocellulose
membrane can expose a photographic film to reveal the expression level of the target
protein.
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8.1.2 Methods
In the end of the culture period, cell layers from trial #7 were scraped from the
upper sides of the inserts from EC only, CO and CO+aECM samples, respectively. 4
replications from each sample were dedicated to contribute cells for this study. The cell
mixtures were solubilized with lysis buffer containing 5mM EDTA, 10mM Tris buffer,
125 mM NaCl, 1% Triton-X 100, and protease inhibitor cocktail (Thermo Scientific).
The cell lysates were subjected to 10% SDS-PAGE resolving gel electrophoresis. The
10% resolving gel was capable of separating proteins in the molecular range of 19-90
kDa, casted by mixing 4ml H2O, 3.3ml 30% acrylamide, 2.5ml 1.5M Tris (pH = 8.8),
100µl SDS, 100µl 10% APS (ammonium persulfate solution) and 4µl TEMED
(N,N,N’,N’-tetramethylenediamine) (Sigma-Aldrich). The recipe for the stacking gel was:
3.4ml H2O, 830µl 30% acrylamide, 630µl 1.0M Tris (pH = 6.8), 50µl 10% SDS, 50µl
10% APS and 5µl TEMED.
2µl of the protein lysates, 18µl H2O and 20µl 2× SDS gel loading buffer (Fisher
Scientific) were mixed and heated at 95ºC for 5 minutes in a dry bath. The heating
procedure caused the proteins to unfold and bound to the negatively charged SDS
molecules. The heated protein mixtures were placed on ice to cool down for 3-5 minutes
and then, 15µl of each protein mixture was loaded into designated lanes on the gel,
respectively. 10µl of EZ-RunTM pre-stained protein ladder (Fisher BioReagents) was
loaded into a lane in the same gel to provide molecular weight indications. Alongside the
protein lysates, a 15µl of the occludin recombinant protein (molecular weight≈ 60 kDa)
purchased from Novus Biologicals (Littleton, CO) was also added into a lane on the gel
serving as positive control. The electrophoresis was run in the electrophoresis chamber
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(BioRad, Hercules, CA) at 100V for approximately 90 minutes through the end of the gel.
The electrophoresis contained 0.25M Tris base, 1.92M Glycine and 20% w/v SDS.
At the end of the electrophoresis, the gel was carefully separated from the
assembly and put into the container with transfer buffer (BupH Tris-glycine buffer: when
dissolved in 500mL of 20% methanol, each pack yields 25mM Tris, 192mM glycine, pH
8. Fisher Scientific). The nitrocellulose membrane, filters and sponges were presoaked in
the container for 20 minutes. A sandwich was assembled in the following order: the
negative electrode, a piece of sponge, a piece of filter paper, the SDS-PAGE gel, the
nitrocellulose membrane, another piece of filter paper, another piece of sponge, and
finally the positive electrode. Figure 40 shows a picture of how the gel transfer sandwich
was assembled during the experiment. The assembly was placed in the transfer tank
(BioRad) full of transfer buffer and transferred for 1 hour at 50V, 164mA at room
temperature.

Figure 40 Sandwich assembly for Western Blot gel transfer
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In the end of the transfer procedure, proteins were transferred onto the
nitrocellulose membrane. The nitrocellulose membrane was blocked with 5% BSA
(Fisher Scientific) for 1 hour with agitation. The membrane was then washed 3 times for
5 minute with TBST (Tris Buffered Saline, with Tween® 20, Sigma-Aldrich with
agitation. Then the membrane was incubated with primary antibody for 16 hours at 4°C
with agitation. The primary antibody was 1:20 (5μg/ml) rabbit anti-occludin (US
Biological) diluted in TBST containing 5% BSA. The incubated membrane was washed 3
times for 5 minutes each with TBST with agitation. Then the membrane was further
incubated with secondary antibody (US Biological) for another hour at room temperature
with agitation. The secondary antibody was 1:10000 HRP conjugated anti-rabbit IgG
diluted in TBST with 5% BSA. Then the membrane was washed another 3 times for 5
minutes each with TBST with agitation.
The final membrane was soaked in 10ml of LumiGLO Reagent (0.5ml
20XLumiGLO, 0.5ml 20X Peroxide, 9ml water) (Cell Signaling Technology, Inc.
Danvers, MA)with gentle agitation for 1 minute. The immunoreactive bands were
exposed onto Pierce CL-Xposure films (Fisher Scientific) in the dark room.
8.1.3 Results and Discussion
The scan of the exposed film from the experiment is demonstration as in Figure
41. Clearly the detected protein bands all showed up at around 60kDa of molecular
weight, which was the predicted molecular weight of occludin. In the picture, lane 1
represented the protein band from the occludin recombinant protein positive control.
Lane 2 represented the protein band from the protein mixture from astrocytes alone
samples. Lane 3 represented the protein band from the protein mixture from EC alone
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samples. Lane 4 shows the protein band from the protein mixture from CO samples. Lane
5 shows the protein band from the protein mixture from CO+aECM samples.
It was clear from the picture that no occludin protein band was detected from the
EC alone or astrocytes alone samples. Both CO and CO+aECM samples displayed
detected occludin protein band on the film, while the chemiluminescent intensity of the
CO+aECM samples was apparently stronger than that of the CO samples. This could be
interpreted as there were more occludin expressed on the CO+aECM samples than the
CO samples.

Figure 41 Scan of exposed film from the Western Blot analysis of occludin
Because of the very limited funding availability during the time of the
experiment, the Western Blot analysis was only carried out once for one of the tight
junction proteins, occludin itself for one trial. However, the result was obvious enough to
show the different occludin express levels on different sample setups, which agreed with
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the initial assumption that the endothelial cell layers from the CO+aECM samples
expressed the highest level of occludin, while endothelial cells cultured alone or
astrocytes cultured alone were not able to express enough level of occludin if there was
any, to be detected by this effective protein detection method. The endothelial cell layers
from the CO samples were able to express a level of occludin in this analysis, but the
amount was smaller than that from the CO+aECM samples.
8.2 Immuno-Fluorescence Microscopy
The expression of occludin was further examined by immuno-fluorescence
microscopy. Since there are many similarities between immuno-fluorescence microscopy
and Western Blot analysis, much briefer language will be used to describe this method in
the following sections.
8.2.1 Introduction to Immuno-Fluorescence Microscopy
Immuno-fluorescence microscopy method is usually used to visualize the
subcellular allocation of biomolecules of interest. Similar to the Western Blot analysis,
two types of antibodies are included in immuno-fluorescence microscopy studies: the
primary antibody is usually raised in another species against the target protein to detect
the protein; the primary protein will be recognized by the secondary protein which is
conjugated with a fluorescent dye. The examples of fluorescent dyes are fluorescein and
rhodamine. At last the immuno-fluorescent labeled culture samples can be studies using a
fluorescence microscope or a confocal microscope.
8.2.2 Methods
Select samples from Trial #8 were chosen for the immuno-fluorescence
microscopy study. The samples included EC, CO and CO+aECM. At the end of the

101

culturing period, cell layers were treated immediately with ice cold 0.2% Triton X-100
for 2 minutes after removing the culture media. After the immediate treatment, the cell
layers were fixed directly on the culture inserts by gently adding 3% paraformaldehyde
(Sigma-Aldrich) directly into the inserts. The cell layers were being fixed for 30 minutes
at room temperature. After fixation, the samples were treated with ice cold 0.05% Triton
X-100 in PBS for 5 minutes. Then, the samples were blocked by 5% BSA solution in
room temperature for 1 hour. After blocking, the samples were incubated with 1:20 rabbit
anti-occludin primary antibody (US Biological) in room temperature for 1 hour. The
samples were further incubated with 1:5000 FITC-conjugated goat anti-rabbit IgG (US
Biological) in room temperature for 30 minutes. FITC is Fluorescein isothiocyanate, a
derivative of fluorescein and is widely used in immuno-fluorescence microscopy. The
samples were examined by IX81 Motorized Inverted Microscope (Olympus) at the
excitation/emission wavelength at 495nm/521nm.
8.2.3 Results and Discussion
The immuno-staining results for CO and CO+aECM samples are shown in Figure 42.
The fluorescence image of EC sample was completely dark so it was not shown here.
Tight junction protein occludin’s contours could be observed from both co-cultured
sample setups. However, the cells contours marked by the stained occludin were more
obvious on the CO+aECM samples than those of the CO samples. There was a blurred
pattern of green color on Figure 42(A) which could be the noise coming from the PTFE
fibers from below the cell layer but not the stained protein itself. The cell silhouettes on
Figure 42(B) were much easier to distinguish than those on Figure 42(A) because of the
higher density of the stained occludin on the CO+aECM samples. The results indicated
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more occludin was expressed on the CO+aECM sample than on the CO sample, while
there was no detectable occludin on the ECM sample. Astrocytes in both co-culture
samples helped induce the endothelial cells to express the tight junction protein occludin,
while the aECM was important for the endothelial cells to form better tight junctions as
shown in Figure 42.
A

B

10 µm

Figure 42 Immuno-fluorescence microscopy image of endothelial layers from coculture samples: (A): CO sample; (B): CO+aECM sample
8.3 Summary
This chapter focuses on the expression of occludin, one of the earliest identified
proteins on BBB endothelial tight junctions. Even though due to the shortage of research
funding, only limited experiments were carried out for only one type of tight junction
protein, the positive results from both experiments from two sets of trials are persuasive.
Endothelial layers from both of the co-culture samples were capable of expressing
occludin while the endothelial cells cultured alone were not able to express if any,
detectable amount of occludin by this particular analysis. The CO+aECM samples were
superior to the CO samples in terms of occludin expression level. Because occludin does
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not exists on astrocytes, the higher occludin expression level could be accredited to the
contribution of the aECM, which was assumed to help the endothelial cells exhibit more
BBB capillary like characteristics including tight junction proteins expression.
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CHAPTER IX ASTROCYTE LOSS ANALYSIS
9.1 Introduction
In the co-culture samples, astrocytes growing on the basal sides of the inserts had
to fight the gravity pull and a portion would inevitably fell onto the well bottoms where
the inserts sat. The amount of astrocytes that fell from the basal sides of the insert
membranes from selected co-culture samples were evaluated by in vitro colorimetric
Sulforhodamine B (SRB) assay. SRB is a fluorescent dye widely used in the
quantification of cell toxicity assay. The dye binds to cellular protein and when
solubilized in base, the optical absorbance can be measured at the wavelength of 520nm
by a micro plate optical reader. By obtaining optical density readings from the micro
plate reader machine, cell density can be determined based on the optical absorbance vs.
cell density calibration curve carried out experimentally for each specific type of
cell(102).
9.2 Methods
At the end of culturing period, the well bottoms of the CO and CO+aECM
samples from Trial #7, #8, #9 and #11 on the 24-well plates were fixed for 30 min by
50% trichloroacetic acid (TCA) purchased from Sigma-Aldrich (St. Louis, MO).
According to the protocol, the fixed wells were rinsed 4 times with tap water and air
dried before SRB staining. It took 30 min for 0.1% SRB (Sigma-Aldrich, St. Louis, MO)
diluted in 1% acetic acid (Sigma-Aldrich, St. Louis, MO) to stain the dried well bottoms
where the astrocytes fell onto. The stained samples were rinsed with 1% acetic acid to
remove unbound dye and dried over night until no standing moisture was visible. Finally,
the stained wells were solubilized by 10 mM Trizma base (Sigma-Aldrich, St. Louis,
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MO) solution and optical absorbance was measured at 520nm by a GNEios TECAN
micro plate reader (Phoenix Research, Candler, NC). The 24-well plates were shaken for
5 min before measurement to facilitate the extraction, solubilization and mixing of SRB
dye molecules. The final experimental results were expressed as the number of cells
calculated based on the linear relationship between the optical absorbance and cell
numbers.
9.3 Astrocytes Cell Number SRB Calibration Curve
Cell number calibration curve for astrocytes was generated to facilitate the
conversion between optical densities to cell numbers. Briefly, 6 different concentrations
of astrocytes cell mixtures were seeded onto the 6 column of 24-well plate, each well
with 4 replications. The

6 different cell numbers were: 0.25×104cells/well,

0.5×104cells/well, 1×104cells/well, 2×104cells/well, 4×104cells/well, and 8×104cells/well.
After the cells are seeded onto the well bottoms, they were allowed 24 hours in order to
attach to the bottoms before fixation. Following the same procedure as aforementioned,
the well bottoms were fixed, rinsed and stained by SRB. The picture shown below is a
demonstration of how the SRB stained and dried well bottoms looked like for the
calibration plate.
The obtained calibration curve is as following graph shows. This graph shows a
linear relationship (R2 = 99.86%) between the well cell density and the optical
absorbance so it would be pertinent to use the curve fitting linear equation (y = 4×10-60.001) to predict the cell numbers using optical absorbance obtained from the
experiments.
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Figure 43 Dried SRB stained 24-well plate for the calibration curve
9.4 Results
SRB optical absorbencies from the well bottoms of 4 trials were obtained, with 4
replications of each trial, respectively. Furthermore, in order to reduce possible
background noise generated from the plastic wells, the optical absorbencies were taken
each time for the blank wells and the values were subtracted from the readings to get the
normalized final values. The normalized optical absorbance values were then calculated
using the equation obtained from the calibration curve, and the results are displayed as
following table in cell numbers.
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Figure 44 Astrocytes SRB Calibration Curve
Table 7 Cells fell onto well bottoms from different co-culture setups in 4 trials
Co-culture Samples
Cells on well bottom
CO Samples

(cells)

Trial

Trial

Trial

Trial

#7

#8

#9

#10

75942

78856

79938

76975

1004

801

1560

42069

38658

42950

1223

1712

1272

Standard Deviation (cells) 1460
CO+aECM
Samples

Cells on well bottom
(cells)

37400

Standard Deviation (cells) 1172

Thus in summary, the average value of astrocytes fell onto the well bottoms from
the 4 trials and their standard deviations are shown in Figure 45.
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Figure 45 Astrocytes cell loss analysis
9.5 Discussions and Summary
As one of the minor study of co-culture model characteristics, the SRB staining
study was performed to check the number of astrocytes fell onto well bottoms during the
whole culture period. For both co-cultured samples, since the astrocytes were growing on
the basal sides of the inserts, the cells would inevitably fall onto the wells because of
gravity. However, the SRB assay revealed the fact that the CO+aECM samples had much
less astrocytes loss from the basal sides of the inserts. Cell loss from the two setups were
proven to be statistically significant by t-test analysis when α = 0.05 (p = 1.98×10 -7). The
astrocytes loss results may due to the fact that astrocyte itself is involved with secretion
of cellular adhesion molecules, a component of the extracellular matrix. With the
existence of aECM, the co-culture present as a better mimic of the real BBB and the
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extracellular components from the aECM helped the astrocytes on the basal side “stick”
tighter to fight the pull from gravity. The integrity of the BBB is also partly revealed in
part by this study. On the other hand, the number of cells revealed in this study should
not be taken as the actual amount of cells that fell onto the well bottoms. Any cell that
fell had the tendency to re-attach to the well bottom and would most likely to reproliferate. The most accurate way should be a day-by-day measurement of the cell
number on the well bottoms. But, this would need excessive amount of cell culture
apparatus in this minor study of the dissertation and was not considered to be worth
doing. Anyway, since cell would grow in all the wells when they fell, we could still use
the significantly different numbers in the assessment of astrocyte adhesion to the insert
membranes.

In the future, analyses of the cellular component of the aECM are

recommended to be carried out to better understand the mechanism of this phenomenon.
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CHAPTER X CONCLUSIONS
The main focus of this specific study can be broken down into two independent
but related facets: 1. to investigate the feasibility of using commercially available
immortalized cell lines as an effective alternative of primary cell cultures in BBB in vitro
modeling; 2. to explore the effect of astrocyte derived aECM as an endothelial cell
seeding scaffold on in vitro BBB co-culture models.
Even though primary cell cultures seem to have higher in vitro – in vivo
correlations in terms of trans-endothelial resistance values and expression of tight
junction markers, the drawbacks are also quite obvious. First and foremost, the source of
cells is limited and unreliable, let alone meeting the requirement of desirable large
quantity; second, variations of cellular features are inevitable among different operators;
third, primary cell culture can be only maintained for very limited passages before losing
their characteristics, apoptosis and altered cytokine susceptibility; last but not least, the
demand for primary cells created ethical problems for scientist in using animals (103). On
the other hand, immortalized cell lines have their attractive advantages. They are ready to
be purchased from reliable commercial sources at relatively low costs in comparison with
all the work and effort that have to be put into primary cell culture. Immortalized cell
lines get the name because of a procedure in the immortalization where cells are usually
transfected by SV-40 virus which enables the cells to virtually escape from normal cell
cycle. Immortalized cell lines can usually be cultured for more than 25 passages before
any cell crisis, enabling large scale experimental design. The passage numbers of the
cells used in the 12 trials of assessment were from passage 2 to passage 10. No
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significant difference was observed between samples made from different passages of the
cells, thus the consistency of the in vitro samples was made possible.
The in vitro “CO+aECM” model demonstrated several important characteristics
in terms of TEER values and occludin expression comparable to literature values such as
described by Garcia-Garcia et al. and Hurst et al.. The addition of one extra layer of
aECM may be argued to be the reason of higher TEER values and lower mass transport.
However it is important to notice the higher tight junction protein occludin expression
qualitatively demonstrated by both Western Blot and immuno-fluorescence microscopy.
It was also interesting to discover that CO+aECM samples had less cell loss on the basal
sides of the inserts comparing to CO samples in the end of the experiments. This
phenomenon may indicate the important role astrocytes played in extracellular matrix
secretion as well as the interaction between astrocytes and endothelial cells. In the
meanwhile, it was experimentally observed that the aECM gradually became less visible
throughout the 9-day culture period. This phenomenon can be explained by the extra
cellular components secreted by the astrocytes which were gradually consumed by the
co-culture system and thus the “extra” layer of aECM was diminishing over time.
However, the trends of the quantitative results (TEER and transport) didn’t change over
time with the disappearing of the aECM. This suggested that the aECM were better
mimic of the blood-brain barrier basement membrane and helped the ECs to maintain the
tight junction features. Astrocyte derived aECM thus proved its important role in
providing a suitable basement membrane environment for the tight junction formation in
every aspect.
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A relevant in vitro BBB model should be reproducible, contain cells that are able
to retain their functional, morphological and barrier properties. The results of the
evaluation of 12 trials of experiments, at least 3 trials contributed to a specific aspect of
the samples, all carried out under the same experimental conditions, suggested that the
co-cultured sample with aECM serves as a feasible in vitro BBB model, where the aECM
provides a biomimick of a basement membrane that is similar to the actual brain
microvasculature environment for the endothelial cells. The novel co-cultured BBB in
vitro model with aECM was also proved to be reproducible, reliable and easy to manage
by using commercially available immortalized cell lines, providing a convenient and cost
effective alternative platform for in vitro drug testing and development.
Even though the in vitro model has been demonstrated as a promising relevant
BBB model, some works were initially planned but was not able to be accomplished due
to the availability of funding and on campus facility. As the future direction of this
particular research, possible supplement in the growth media may be explored to further
enhance the tight junction formation. More transport studies of more diverse selection of
compounds are suggested to be performed on the established in vitro model, so passive
transport and active transport of different compounds can be evaluated. And to better
understand the in vitro model, characterization of the molecular components in the aECM
is suggested. If possible, assay of p-Glycoprotein should also be employed in the further
studies.
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